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Abstract
Globally, the eradication of malaria has been challenging due to the problem of 
resistance that past and currently available drugs exhibit. This is exacerbated by the 
inherent need for anti-malarial drugs to be affordable to the poverty-stricken majority 
that is primarily affected by this burden.
This research has focused on the development of potential inhibitors of 1-deoxy-D- 
xylulose-5-phosphate reductoisomerase (DXR), an essential enzyme in the mevalonate- 
independent pathway for the biosynthesis of isoprenoids in Plasmodium falciparum. DXR 
mediates the isomerisation and reduction of 1-deoxy-D-xylulose-5-phosphate into 2-C- 
methyl-D-erithrytol 4-phosphate.
This enzyme has been determined to be a target for the development of novel anti­
malarial agents and extensive molecular modelling has been undertaken to develop 
inhibitors that fit into the DXR active site. The in silico docking data have been used to 
inform the design and synthesis of various N-benzyl-substituted phosphoramidate ligands 
that were determined to have potential as novel substrate mimics of fosmidomycin, a 
known DXR inhibitor.
Synthesis of the N-benzyl-substituted phosphoramidate ligands involved a nine-step 
sequence commencing from diethyl phosphoramidate. In all, some 40 compounds 
have been prepared, some of them new, and were fully characterized using NMR. 
Attention has also been given to the mass spectrometric fragmentation patterns exhibited 
by selected intermediates. Four of the final products were evaluated for in vitro 
antimalarial activity using a PLDH assay and exhibited IC50 values < 100 |aM.
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1. Introduction
1.1. History of malaria
The Homo sapiens species has been infected with hundreds of parasites some of which have 
been responsible for serious diseases and illnesses throughout its evolution. The origins of 
these diseases were often misunderstood or unknown as knowledge of microorganisms was 
limited. However, the symptoms described in many ancient texts can be linked to diseases 
we know today. Malaria is among one of the oldest human diseases in recorded history and 
it continues to be the cause of death for millions of people all over the world.1 The existence 
of this parasitic disease can be traced far back in history in various parts of the world, where 
documented evidence confirms the presence of malaria throughout the millennia.
Written records about malaria can be dated for thousands of years to the period of Egyptian 
medicine (3000 -  400) BC as well as in some sub-continent writings.1,2 There are literature 
references to malaria from many countries; in India, ancient scriptures as well as songs 
contain references to fever-like symptoms that are considered to have been about malaria,3 
while in China, malaria had been discovered and described in the Nei Ching as fevers.3 Even 
though knowledge about malaria was limited, it is evident that this disease has been a 
medical concern for many years. Numerous occurrences of epidemic fever-related deaths 
have been attributed to malaria; these include the hypothesis that Alexander the Great died 
from malaria on his way to India.3
Competition for research attention and funding for diseases such as acute lower respiratory 
infection, TB (tuberculosis), HIV/AIDS (human immune virus/ acquired immune deficiency)4 
has grown, but malaria continues to be prevalent and remains a challenging illness in many 
parts of the world. Recently, the WHO (world health organisation) has classified HIV/AIDS, 
TB and malaria as priority diseases in the world,5 posing the highest risk to human health. 
Resistance has emerged to currently available medicines for all these diseases and no 
vaccine has yet been developed for any of them.5 There are promising malaria vaccines such
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the RTS.S candidate but these have yet to completely eliminate the parasite.6 Major 
research efforts are clearly essential if we are to eradicate these epidemic illnesses.
In the early stages of research there was minimal knowledge about malaria and it required 
years of investigation to finally establish the cause of the infection and link the symptoms 
displayed by the host with the vector of the parasite. Malaria was explained in ancient times 
as an evil spirit and by the well-known miasma theory,7 which led to the Italian name of 
Malaria meaning "bad air". The theory was conceptualised when malaria reached epidemic 
proportions in Greece by the Greek physician, Hippocrates.8 It was believed that the illness 
arose from contaminated air. After the discovery of bacteria by Antonie van Leeuwenhoek 
in 1676,9 as well as the experimental evidence demonstrated by Louis Pasteur that diseases 
are not spontaneously generated but are caused by certain microorganisms and bacteria,9 
research in microorganisms accelerated. Human parasites such as trematodes, nematodes 
and pathogenic protozoa are responsible for many diseases10 and it is essential that we 
understand their entire function and life cycles. Increased knowledge of parasites, in 
general, has promoted further research on the malaria parasite, in particular. Initial research 
was based mainly on observations with no scientific understanding, notions such as the 
initial connection of the illness to mosquitoes by Patrick Manson9 which opened the 
opportunity to the provision of scientific evidence.
The discovery of the Plasmodium parasite in the red blood cells of infected patients by a 
French physician Charles Laveran in 18801 sparked initial interest in the malaria parasite by 
researchers. Laveran was working as a surgeon in Algeria in 187811 when he noticed a black 
pigment on dead soldiers in the mortuary. He then started examining the bodies of soldiers 
who were suffering from this unknown disease.11 In 1897, Ronald Ross then discovered the 
parasite vector to be a certain species of mosquito, a fact which he demonstrated by 
deliberately infecting birds with malaria and then isolating the parasite from the salivary 
glands of the mosquitoes which had fed on the infected birds.12,13 This information 
narrowed the species of interest which was essential for a more specific or targeted 
approach. Various researchers assisted in understanding the malaria parasite after Laveran;
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these include Camillo Golgi, a neurophysiologist who identified the merozoite stage of the 
parasite, William MacCallum who, while working as a medical student at John Hopkins, 
discovered the reproductive stages of the malaria parasite.11
Once some knowledge on the biological and cellular level of the parasite become available, 
scientists looked towards analysing the parasite's lifecycle in its entirety. In order to move 
toward a drug treatment plan, extensive research was conducted on the parasite as well as 
those affected by it. Malaria is an intracellular protozoan parasite from the genus 
Plasmodium14 that is carried by the female Anopheles gambiae mosquito as the vector; the 
mosquito then infects the human host.15,16 There are over 400 species of the Anopheles 
mosquitos and only approximately 30-40 of these can transmit malaria.15-17 Four of these 
species are commonly involved in the infection of human hosts, namely Plasmodium vivax, 
P. ovale, P. malariae and P. falciparum,16 with P. falciparum being the most deadly. In 2008, 
the WHO identified a fifth species of malaria parasite; Plasmodium knowlesi, which 
originally infected primates and which also caused malaria in humans.18 The origin of P. 
falciparum in humans can be traced back to cross-species transmission through Anopheles 
mosquitos which were able to infect apes and then transfer this strain of malaria to
humans.19
The different malaria parasite species pose health threats to humans in various and unique 
ways. These differences include the incubation period that the parasite has in both the 
vector and the host, the haemazoin structures that each species forms during haemoglobin 
intake20 (sometimes used as a mechanism to diagnose the species of infection), and the 
genetic make-up of each species,21 which opens other channels for gene therapy where 
drugs can be developed specifically for each Plasmodium species. P. vivax is the most 
common species of malaria parasite and can be found in far more parts of the world22 than 
the other species. However, this species is believed to be more benign than other 
Plasmodium parasites and is often neglected in most research laboratories even though it is 
responsible for up to 80 million infections almost every year in Africa.23 The shape and size 
of the P. vivax haemozoin crystals were found to differ slightly from those of P. falciparum,
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with the P. vivax appearing to be cubic.20 In a study conducted in 29 villages in Papua New 
Guinea evaluating the relationship between parasitic density and age dependent clinical 
tolerance, it was found that P. vivax was the second most deadly Plasmodium species and 
more prevalent in younger patients.24 The parasite target erythrocytes that each species 
prefers also differ significantly. P. vivax parasites prefer to invade immature RBCs while P. 
falciparum invades mostly mature RBCs (red blood cells).23 Both P. vivax and P. ovale species 
have the ability to remain inactive or dormant in the liver stage while P. malariae and P. 
falciparum do not;25 this allows the former species to re-appear and cause infection relapses 
months after treatment of the first infection.
The majority of research efforts are focused on the P. falciparum species but it is important 
to note that, in most of Sub-Saharan African countries, 1% to 7% of malaria cases can be 
attributed to P. ovale and P. malariae.26 The P. falciparum haemazoin is similar, in some 
respect, to all the human-infecting species but significantly different to the bird-infecting 
Plasmodium species.20 Haemazoin structures of human-infecting species are still different 
enough to be distinguishable for diagnoses. In many high risk areas in the world, co­
infection across Plasmodium species is common,27 and the treatment of one species 
significantly affects another.
According to the WHO, 99 countries in the world were confronted with ongoing malarial 
infections in 2011.28 The malaria burden covers some parts of South America and Asia, but 
the majority of malaria deaths are occurring in sub-Saharan Africa.29 Efforts to reduce these 
mortality rates have been put in place by the WHO with 55 countries approaching WHA and 
RBM targets, which aim to reduce malaria cases by 75 % by the year 2015.28 These initiatives 
have been established to monitor progress in the fight against malaria.
Malarial infections are more common amongst young children and pregnant women.30 It is 
therefore important that new drugs are highly pure and safe. The parasite is more prevalent 
in poverty-stricken areas of the world;31 this can be seen by the correlation of high malaria 
rates with developing as well as third-world countries,28 with countries with low GDP (gross 
domestic product) growth being at particularly high risk whereas high GDP growth ratesPage 16
generally experience low malaria risk.32 It is therefore very important that new drugs are 
prepared from affordable starting materials in order to allow for affordable drug treatment. 
Even with such gloomy statistics there is hope, as there has been a 25 % global decrease 
over the three years since 201033 in the number of people who have died due to malarial 
infections. This indicates a move in the right direction that will, hopefully, lead to the 
eventual eradication of the disease. Current research is focused on the development of 
novel drugs with novel modes of action to overcome limitations of current drugs.
The major challenge facing malaria research is the re-occurring issue of anti-malarial 
resistance.28 Anti-malarial drugs which were once effective in malaria treatment have been 
affected by the drug resistance phenomenon which is predominantly exhibited by the P. 
falciparum species.34,35 Consequently, there is an urgent need for novel drugs that can 
combat resistance and effectively treat human malaria.
1.1.1. Life-cycle of the malaria parasite
The first step in understanding the Plasmodium parasite is to analyse its life-cycle; this 
allows for an understanding of its functioning and mechanisms of survival. The Plasmodium 
parasite passes through different stages as well as various morphologies and cellular 
environments.36 In some ways this is advantageous as it provides numerous potential 
targets for anti-malarial drug discovery with opportunities for novel modes of anti-malarial 
action. The parasite passes through six forms during its life-cycle in the malaria vector, 
namely female or male gametocytes and the corresponding gametes, zygote, ookinete, 
oocyst and sporozoite.4 In the human host, the parasite has two stages following infection, 
the liver stage and the erythrocyte or blood stage.37 In the mosquito, the parasite undergoes 
its reproduction stage involving the formation of new parasites capable of infecting a new 
host during the process of feeding. The stages of the parasite life-cycle can be represented 
from vector to host or from host to vector. The life-cycle of all Plasmodium species is similar 
with slight differences at each stage of maturation.
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Generally, the cycle can be explained beginning from the initial bite of human host, where 
the parasite is delivered via a blood meal, the sporozites travels to the liver where it 
matures in the hepatocytes to merozoites which invade RBC and replicate asexually, 
invading further RBC. The merozoites may develop into gametocytes which are taken up by 
the a mosquito, from ingestion via a blood meal. These further develop to gametes, which 
sexually reproduce to produce zygotes, from which there is eventual production of the 
sporozoites that are transmitted to human host during the next blood meal.
The first stage in the cycle (Figure 1) begins when the female Anopheles mosquito 
penetrates the tissue of the human host and deposits sporozoites37 through saliva during a 
blood meal. Sporozoites are slender haploids which enter the blood stream through the 
mosquito's salivary glands. From the host's bloodstream the sporozoites are transported to 
the liver.38 Fewer parasites leave the bite site and enter the human host liver than those 
present during initial infection.39 This is an excellent point for targeted termination as the 
parasite numbers are reduced and might be easier to kill. However, this stage is completed 
within 48 hours and diagnosis has to be timely.40 The process by which the parasites leave 
the bite site and are transported to the liver is not fully understood. There are not many 
drugs that target this stage of the parasite life-cycle, mainly due to the short time in which 
infection develops.
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Figure 1. The life-cycle of the Plasmodium parasite in the human host.58 
The parasites then commence a maturation stage in the liver where they go through various 
stages from the hypnozoite form (Figure 1); this is also known as the hepatic phase38 in 
which they either remain dormant or continue maturing over several days.41 This 
distribution is significant in some species, such as P. vivax, which prefer to remain in the 
dormant stage for longer periods. The liver stage of the malaria parasite was only 
discovered in 1948;42 until then early drug discovery had been mainly targeted at the blood 
stage of the life-cycle. The newly-evaded hepatocytes then become schizonts as in Figure 1, 
which when mature continue on to the blood infection stage.43 The schizonts invade RBCs, 
preferably mature red blood cells40 although different species of Plasmodium schizonts have 
different RBC preferences. Since the schizonts are maturing in the liver, diagnosis is 
impossible as they exhibit masked immunity.40 This stage of maturation shows no symptoms 
of illness. Maturation occurs over a few days before the mature schizonts burst out of the 
liver.44 When the schizonts mature they become merozoites; this is also known as a pre­
erythrocytic or exo-erythrocytic phase.41 The mature schizonts are then released in large 
numbers into the blood and begin to interact with the host's red blood cells.43 Liver-stage 
drugs would be ideal as these would terminate the parasites prior to their maturation or 
invasion. Page 19
The final stage of maturation known as the intra-erythrocytic or ring stage45 occurs when 
the liver bursts and releases merozoites, which at this stage, undergo asexual reproduction 
and multiply.46 The production of infected RBCs also known as iRBCs47 from the initial 
merozoites is complex and numerous techniques, such as live cell imaging and electron 
microscopy, have been used to investigate what occurs at this stage of the infection.41 Once 
this asexual stage ends (typically 48 hours after infection), the first matured merozoites are 
produced and released into the bloodstream40 and go on to infect more RBCs and thus 
results in the accumulation of iRBC (infected red blood cells) in the host cells. This 
continuous invasion weakens the host's immune system. The merozoites cannot be 
detected inside the RBC and are masked to the immune system, allowing them to undergo 
numerous cycles of asexual cell division which rupture the RBCs,41 releasing more 
merozoites into the bloodstream that invade more host cells. The RBC rupturing leads to 
small waste particles being left in the blood which result in the host displaying symptoms 
such as fever, chills, headaches, diarrhoea, nausea and body aches.48 These are the clinical 
symptoms of malaria.
The malaria parasites use combinations of movement and membrane fusion to attach to 
and invade the RBCs41. These include use of the actin-myosin motor to bind to the surface of 
the target protein and passive diffusion to enter the host cell. 49 The cleaved merozoites 
utilise an anchor made from actin-myosin filaments in the membrane to move sporozoites 
and invade the RBCs.50 The RBC membrane comprises a lipid bilayer covering a protein 
network,45 and the parasite needs appropriate strategies for traversing the cell wall. Binding 
to the motor is highly selective and only occurs in the Apicomplexa41 where an opportunity 
for targeted termination arises. All the stages of maturation of the parasite are completely 
dependent on and facilitated by the host cell.51 This is why there have been extensive 
studies on the blood stage of the parasite.
About 1% of the merozoites produced then undergo differentiation and become 
gametocytes, a process that takes 9-12 days.51 The newly formed gametocytes develop into 
microgametocytes and macrogametocytes, which form female and male gametes,
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respectively, and which are ingested by a mosquito during a blood meal.38 This is yet 
another potential point for targeted termination of the parasite as relatively fewer 
merozoites undergo maturation into gametocytes. The remaining 99 % of the merozoites 
produced continue to invade and infect more RBCs, thus multiplying parasites and 
exacerbating symptoms in the human host,38 finally leading to death. The next essential 
stages in the life-cycle of the Plasmodium parasite take place in the vector, i.e., in the 
female Anopheles mosquito (Figure 1). After the gametocytes have been ingested by the 
mosquito through the blood meal, they escape the host RBCs and begin the sexual 
replication stage.52 In the female Anopheles mosquito, the female and male gametes 
develop in the mid-gut,53 where they develop to infect another host during another blood 
meal. There are various strategies for anti-malarial drugs that target the vector at the stage 
where sexual replication occurs. The growth or development of the parasite once it enters 
the vector depends on the temperature and type of parasite species.54
The male macrogametocytes emerge from the RBCs that are ingested by the mosquito 
during a blood meal and go through a 3-step process of maturation; they grow external 
flagella as seen in Figure 1, after which they fertilize the female microgametocytes.55 The 
process of gametocytogenesis which follows is not fully understood,56 although some 
studies show that attempts by the mosquito's immune system to fight off the parasite 
triggers the sexual development stage. The gametocytes travel further up the mid-gut of the 
mosquito and develop into zygotes which form mature ookinetes57 which can either remain 
as they are or develop into oocysts. The oocysts finally produce a large number of 
sporozoites57 which travel to the salivary glands of the mosquito and are transferred into a 
new host when the mosquito obtains its next blood meal.
Relatively little research that focuses on the gametocytes phase appears to have been 
undertaken,56 possibly due to the complexity of their maturation in the RBCs, their masked 
immunity and the fact that this would require vector-based strategies. While various stages 
of the parasites life-cycle have been targeted with anti-malarial drugs that are specific to a 
pathway or phase, challenges remain. These include the problem of resistance.
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1.2. Past and present anti-malarial drugs
Even though malaria was not fully understood, the fever-like symptoms have been treated 
using traditional medicines that formed the bases for anti-malarial drug discovery centuries 
later. Now, each of the known drugs are expected to target a specific pathway, an organelle 
of the parasite and some the mosquito itself. Since the mosquito was known to be the 
vector for malaria,57 the first anti-malaria strategy was to eradicate the mosquito larvae as 
these would be easier to locate than the mobile adults59 using insecticides such as 
Pyrethrum.60 These were used until it became apparent that the cost and the inconvenience 
of having to continuously spray61 would be problematic. Malaria was wide-spread during the 
time of the Second World War (1940-1945)62 and many soldiers died from the disease as 
fighting extended the malaria-endemic to many parts of the world. After the war, a new 
malaria insecticide was discovered; known as DDT (dichlorodiphenyltrichloroethane), it 
would come to be one of the greatest weapons against malaria.63
The initial research for insecticides included natural-occurring derivatives such as 
chrysanthemic acid which was isolated from a flower38 and DDT. While initial attention had 
been on attacking the vector, scientists began to focus on the human host and research on 
anti-malarial vaccines began during 1 9 1 2 . 64,65 However, this approach has proved 
challenging due to the complexity of the parasite's lifecycle.66 The vaccines were expected 
to target various stages of the malaria parasite's maturation in the host65 and to be cheap as 
majority of infections occur in poverty-stricken areas in the world in which storage of 
vaccines in air tight or cold containers would be difficult.66
Use of insecticides as anti-malarial prevention methods was finally introduced by the WHO 
in 1973,67 but DDT as an insecticide was discovered in 1939 by a Swiss chemist, Paul 
Muller.38 Its ability to kill mosquitoes was exploited as a means of eradicating the vector. 
DDT was originally synthesised in 1874. However it was only used as an insecticide in 1939.67 
The insolubility of DDT in water and its solubility in fat68 were expected to preclude certain 
organisms and humans from being affected by DDT. During and after World War II, DDT was 
distributed to many parts of the world. This led to DDT being a cheap and effective way toPage 22
treat and prevent malaria.69 However, there were health risks that were suspected and 
unknown. While exclusion of humans as a DDT target was based on its inability to transverse 
the skin membrane as well as its insolubility in aqueous media, DDT was detected in plants 
which humans then ingested, and small amounts of DDT were thus absorbed into the 
human body.70
The advantageous properties of DDT negated its persistence in the environment as well as 
in other living organisms. Human cells, for example, are made of many fat tissue cells. DDT, 
being soluble in such media, is able to dissolve and bind to these cells. Obvious health risks 
are associated with such occurrences and the one disease researchers were most worried 
about was cancer. Research conducted on rodents showed DDT to be retained within the 
organism with a very long lifetime, as well as to cause cancer.67 In 1972, the use of DDT in 
the majority of the world was banned.67 However, some countries continue to produce and 
use DDT even today. DDT was sprayed indoors or outdoors in areas where mosquitos and 
mosquito larvae persisted and it was discovered to act by affecting the peripheral nervous 
system sodium and potassium (Na+/K+) channels when an insect came in contact with the 
insecticide.68 This leads to muscle spasms which then leads to the paralysis of the insect 
which finally results in death.38
The idea that DDT was a serious health hazard was evoked by Rachel Carson, a marine 
biologist, when she published her book "Silent Spring".71 Even though the book was lacking 
in scientific evidence, it led many researchers to investigate her allegations. It became clear 
that the use of insecticides pose both health and environmental threats and that DDT was 
able to persist in the environment for a long time and thus move up the food chain to affect 
all living organisms.67 These developments highlighted the need for effective anti-malarial 
drugs. The synthesis of new anti-malarial drugs was initially based on natural-occurring 
compounds as well as some known inhibitors of various organelles and pathways in other 
organisms, illustrated in (Figure 2).
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Figure 2. The various Plasmodium parasite cellular organelles that are essential for parasite 
survival and continued invasion of host RBC,72 which represent current and potential drug 
targets and relevant drug classes.
The first class of compounds to be developed as anti-malarial drugs were synthetic quinoline 
analogues of the natural product quinine.73 Synthetic quinolines have a 4-oxo-1,4- 
dihydroquinoline backbone and many are utilised as effective antibiotics or anti-malaria 
drugs today.81 These compounds are considered to target the food vacuole, an organelle 
(Figure 2) with a large number of enzymes that degrades and hydrolyses molecules that an 
organism no longer needs.74 Various models have been hypothesized as to how the food 
vacuole collects and degrades the unwanted haemoglobin75 and to understand the 
mechanisms which the various quinolines exploit. Theories on the role of quinolines as anti- 
malarials include haemazoin polymerisation, their effect on lipids membranes,76 the 
generation of free radicals77 and many others. Quinolines have been used to treat malaria 
for over 300 years76 and, in spite of their limitations, they are still used today. The quinoline 
motif occurs in many naturally-occurring compounds and is known to exhibit anti-bacterial, 
anti-malarial and anti-inflammatory properties78 as well as many other biologically 
important activities. The first of these compounds to be used was the alkaloid, quinine,Page 24
obtainable from Cinchona bark.73 This compound is suggested to have been discovered by a 
Peruvian Indian when he accidentally drank from water that had come in contact with the 
Cinchona bark and found his malarial symptoms alleviated. Once the news spread, 
missionaries who visited Peru exported the knowledge to parts of the Western world during 
the 17th century.80 Since then, numerous medically active derivatives of quinine have been 
synthesised.
Quinine was initially used as a crude extract. In 1820, however, Pelletier and Caventou were 
able to extract and isolate it as a pure compound.82 Early attempts to synthesise quinine 
failed due to its structural complexity;73 this meant that it needed to be extracted from the 
Cinchona bark daily. This was time-consuming and threatened the survival of the Cinchona 
species. Another limitation with the use of quinine is its toxicity; side effects include 
cinchonism, tinnitus, impairment of hearing, headache, nausea, vertigo, vomiting, 
abdominal pain, diarrhoea, loss of vision and, sometimes with higher doses, hypotension.80 
There was also poor patient compliance due to the unpleasant taste of the orally-ingested 
quinine.83 It became clear that new and improved anti-malarial drugs had to be developed, 
a challenge which was spurred by limited access to quinine itself during World War II.
Quinine and its stereoisomer quinidine have been used as first line drugs for malaria in 
many parts of the world; in fact, it is still used in countries like the United States.83 During 
World War II, major research efforts led to the synthesis of various analogues of quinine, 
which include the 4-aminoquinolines, amodiaquine and chloroquine.73 Chloroquine, as seen 
in (Figure 3), is a derivative of quinine that has been used for many years and its 
mechanisms of action has been the topic of considerable research.84 Chloroquine was an 
ideal drug being cheap, readily available and fairly easy to synthesise.83
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Figure 3. The structures of various quinoline-derived anti-malarial drugs: quinine, 
mefloquine, chloroquine, ASA-MQb and ASA-Q.82
The discovery of the formation of the "brown pigmentation" in parasite cells by Giovanni 
Lancisi85 was the initial step in understanding the mechanism of action for chloroquine and 
other quinoline-derived anti-malarial drugs (Figure 3). The dark particles were found to 
accumulate in the food vacuole, an acidic lysosome-like organelle which is responsible for 
degrading haemoglobin and discarding toxic haeme as dark, crystalline haemazoin.86 The 
prevailing theory is that chloroquine interferes with haeme detoxification which is a strategy 
for survival utilised by the parasite.85 The parasite takes up haemoglobin from the host in 
order to provide itself with essential nutrition for cell survival.
Another targeted mechanism that occurs in the food vacuole is haemoglobin hydrolysis,77 a 
process which is interrupted by protease inhibitors and artemisinins. Proteases are 
commonly-occurring enzymes present in most living organisms, and are responsible for the 
degradation of proteins into amino acids in various catalytic and regulatory pathways.87 In 
the malaria parasite, these proteases (plasmepsin I, palsmepsin II and falcipain) are 
responsible for the degradation of haemoglobin77 and for the rupture of RBCs. Research on 
protease inhibitors has been constricted by their ubiquitous nature,88 but cysteine protease 
inhibitors have shown potential as anti-malarial drugs.88 Protease inhibitors such as 
fluoromethyl ketones and vinyl sulfones77 have been seen to exhibit anti-malarial activityPage 26
but are toxicity towards the human host.89 During the Vietnam War, quinoline derivatives 
had been used so commonly that their efficiency was rapidly eradicated and, moreover, 
resistance was rising in other parts of the world.91 Sometimes, it is essential that we look to 
the past to change the future, and this approach led to the discovery of the artemisinins. 
Artemisinin (Figure 4), also known as qinghaosu, is a natural extract from the plant 
Artemisia (or qinghao) which has been used in China to cure common fevers and pain for 
decades.90
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Figure 4. The structure of qinghaosu or Artemisinin as well as the various synthetic 
analogues that contain different R-substituents which allow for the solubility that 
artemisinin lacks.96
In 1967, the Chinese government assembled a group of researchers, known as the 523 
research programme,92 who were instructed to extract and test various Chinese herbs and 
plants for anti-malarial activity.93 Artemisinins was then identified to be the active 
component in the extracts that were evaluated. Although artemisinin was active against 
malaria, it was discovered to be highly insoluble in both water and oil media94 and had a 
short half-life;95 these short-comings prompted the synthesis of various analogues, as seen 
in (Figure 4).
Artemisinins have proved to be effective against all Plasmodium species96 and it is vital that 
its mechanism for inhibition be fully understood. However, the mode of action of these
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compounds has been a source of controversy amongst researchers. The prevailing theory 
involves the generation of free radicals.97 Artemisinin has a 1,2,4-trioxane backbone 
containing a peroxide group93 which is essential for anti-malaria activity; removal of the 
peroxide moiety yielded an analogue without inhibition activity.98 It has been proposed that 
the peroxide binds to haeme Fe2+ to produce an oxygen radical which then becomes a 
carbon-centred radical species,97 while another proposed mechanism involves the 
production of hydroxyl radicals.95 Both of these processes damage molecules that are 
essential for the parasites' survival and reduce the concentration of haeme ions which are 
necessary for the degradation of haemoglobin. The Fe2+ is thus believed to be responsible 
for the activation of the pro-drug artemisinin95 which then produces radical species that are 
responsible for anti-malaria activity.
Oil- or water-soluble derivatives of artemisinin, such as artemether and artesunate 
respectively, are now first-line anti-malarial drugs of artemisinin90 and are used in 
artemisinin-based combination therapy (ACT), which was developed in 1978 with other 
known drugs such as piperaquine, mefloquine, amodiaquine, sulfadoxine+pyrimethamine, 
atovaquone+proguanil, pyronaridine and lumefantrine.99 These combinations allow for the 
rapid elimination of the parasite by one drug, combined with the long life-time that the 
other anti-malarial drug provides. Unfortunately ACT has faced various drawbacks which 
earlier anti-malaria drugs have also suffered, namely, dangers associated with pregnant 
patients and, most importantly, anti-malarial drug resistance.90,100 Numerous studies have 
determined that use of ACT by pregnant women may result in severe malaria, spontaneous 
abortion, still birth or premature delivery.101 The problem is compounded by the fact that 
pregnant women and children are most vulnerable to malaria infection. The issue of drug 
resistance to ACT is also an emerging problem that has been detected on the Thai- 
Cambodian and, more recently, the Thai-Myanmar border.100
The lysosome is the site of degradation for biomolecules such as proteins, nucleic acids, 
carbohydrates and lipids,74 and is targeted by anti-malarial drugs which mainly disrupt the 
parasite's haeme degradation cycle. The ability of the parasite to develop mechanisms to
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modify this step gives rise to resistance and it has become increasingly important that novel 
targets are discovered. The targeting biosynthetic pathways (Figure 2) in the cytosol, 
mitochondria, the plasma membrane and apicoplast are the next logical choices.
The cytosol, also known as the intracellular fluid or cytoplasmic matrix, in which the 
organelles are compartmentalized, is an aqueous solution containing proteins and 
polysaccharides.74 A large number of anti-malarial drugs, such as pyrimethamine, proguanil, 
sulfadoxine, dapsone, gossypol derivatives, chorproguanil and many others, target various 
proteins in the cytosol, which are involved in numerous bio-syntheses as well as the 
regulation of organelle structures.77 The main target for these drugs has been the folate 
pathway, which is essential for the synthesis of nucleic acids and methionine,102 vital 
molecules for Plasmodium parasite DNA replication.
The anti-folates take advantage of the ability of the Plasmodium parasite to produce folates 
upon invasion of a host cell through the condensation of the host's pteridines, para- 
aminobenzoic acid (PABA) and glutamate.102 The parasites' inability to utilise host 
nucleotides103 means that the biosynthesis of these nucleotides must occur in the parasite. 
The anti-folates inhibit vital enzymes used by the parasite in this biosynthetic pathway; 
dihydrofolate reductase can be inhibited by chlorguanide, and dihydropteroate synthetase 
can be inhibited by dapsone, while pyrimethamine and sulfadoxine are able to inhibit both 
enzymes104 and have been used in a combination therapy which is commercially available as 
Fansidar.105 Anti-malarial drugs, present and past, have been identified in traditional plants 
and marine organisms; one such drug is gossypol which inhibits the important glycolysis 
cycle106 in the parasite. Gossypol, a toxic extract from cotton seeds was discovered as an 
anti-malarial drug which inhibits lactate dehydrogenase,106 and derivatives showing 
inhibition of chloroquine-resistant strains are being used as anti-malarial drugs.107 These 
drugs have shown low toxicity and a reduced number of side effects,108 but because they 
compete with the natural substrate, resistance has risen and hence their use has been 
limited.106
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Recently, Hsp (heat shock protein), a group of proteins that have been of interest in cancer 
research, are now being studied as a potential anti-malaria drug targets.107,109 Cancer as well 
as Plasmodia cells utilise Hsp70 when subjected to cellular threat.109 The effect of 
Plasmodium parasite Hsp90 has also been studied. Research linking the emergence of 
resistance to P/Hsp90 (which is over expressed during treatment)110 has suggested that dual 
inhibition of these proteins by an anti-malarial drug would yield a highly effective 
combination therapy without the prospects of resistance. The mitochondria are the main 
source of producing energy for eukaryotic organisms,74 and are responsible for the electron 
transfer chain.111 The mitochondria are a valid target for anti-malarial agents such as the 
anti-malaria drug atovaquone (2-[trans-4-(4'-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-
hydroxy naphthoquinone). Atovaquone is an analogue of ubiquinone, the natural substrate. 
It induces competitive inhibition and binds the enzyme dihydroorotate dehydrogenase.115 
The drug is used in combination with proguanil, another anti-malaria drug, to reduce the 
development of resistance.114 The x-ray crystal structure of the cytochrome bc1 complex co­
ordinated to atovaquone has not been determined. Research using computational 
techniques has indicated potential interactions that the inhibitor may have with the 
complex.116 This combination therapy of atovaquone+proguanil has proved to be an 
effective chemoprophylactic for people travelling to high-risk malarial areas.117
Another approach in anti-malarial therapy involves the disruption of the plasma membrane/ 
cell wall. The plasma membrane is essential for the cellular compartmentalization in 
eukaryotic and prokaryotic cells.74 The membrane is the layer composed of phospholipids 
and protein that protects the interior of cells as well as performing functions such as acting 
as a receptor to stimuli and facilitating transportation of molecules in and out of the cell.118 
The importance of membrane synthesis119 is evidenced by the increase of 500% of the 
population of phospholipids in RBC after infection by the parasite.120 It was discovered that 
quaternary ammonium choline analogues inhibited this membrane biogenesis; these 
analogues were designed and evaluated for potency against malaria.121 An analogue with 
outstanding inhibition was G25, in (Figure 5), which was able to completely clear malaria 
when tested using very low doses; its IC50 value of 0.9 |aM compared very favourably withPage 30
that of the known inhibitor chloroquine (0.8 |aM). Moreover, G25 is active against strains
that show resistance to currently used anti-malaria drugs.122
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Figure 5. The choline analogue, G25.122
These anti-malaria drugs are choline analogues; choline is a nutrient that is necessary in the 
synthesis of membrane phospholipids.123 This bio-synthesis is vital for the Plasmodium 
parasite's survival during its stage of producing merozoites where large numbers of 
membrane biogenesis allows for the parasite to continue the infection of RBCs. However, 
these analogues' bioavailability as oral drugs is low and a solution to the problem has not be 
obtained.124 These compounds show potential not only as anti-malaria drugs but as drugs 
that will address the resistance that some drugs that are commercially available are facing.
Current research in our group focuses on the inhibition of an enzyme in the unique 
organelle apicoplast.125 The apicoplast was only discovered in 1996126 and is a non­
photosynthetic plastid from the Phylum Apicomplexa occurring exclusively in protozoan 
parasites127 which cause diseases such as toxoplasmosis, babesiosis, coccidiosis and, most 
importantly, malaria.128 As a uniquely protozoan organelle the apicoplast provides desirable 
pathways that will exclude the human host. The apicoplast is located close to the 
mitochondrion and, for a long time, it was believed to be a storage site for mitochondria 
due to their close proximity and their small size.127,129 Live cell imaging of the asexual stages 
of the malaria parasite revealed the apicoplast as a separate organelle that goes through 
various morphological changes in each step of maturation.128 The P. /alciparum apicoplast is 
essential for the survival of the parasite and therefore a potential target for anti-malaria 
drugs. Further research on the function, properties, metabolic pathways and genetic make­
up has followed. Page 31
1.2.1. Drug resistance
The emergence of anti-malaria drug resistance can be traced back to 1986 when resistance 
to chloroquine and some of its derivatives was reported.132 Resistance spread from the Thai- 
Cambodia region to the rest of the world.133 Resistance to many more drugs began to 
become apparent and the problem of multi-drug resistance emerged.
The time-span for drugs in clinical use seems to be reducing significantly over the years as 
illustrated in (Figure 6). This is evidenced by the fact that resistance to quinine only became 
evident 278 years after its introduction, whereas recent drugs such as proguanil have been 
faced with resistance only a year after commercial introduction.134 It is therefore evident 
that the Plasmodium parasite has developed mechanisms to develop resistance faster than 
it was able to in the past. There are many factors that determine the emergence of 
resistance including the mode of drug action, natural mutation of the Plasmodium genome, 
the transmission level, patient compliance, host immunity and the drug factors such as half­
life, dosing, pharmacokinetics and cross resistance.134 One such mechanism involves the 
resistance to anti-folates. Anti-folates prevent DNA (deoxyribonucleic acid) replication, 
resulting in reduced synthesis of methionine and conversion of glycine to serine, therefore, 
once the parasite no longer has supplies of methionine and serine cell death occurs.136 The 
dh/r (dihydrofolate reductase) and dhps (dihydropeteroate synthase) are the enzymes that 
anti-folates inhibit but mutations in the genes of resistant strains of these enzymes 132 
prevent the recognition and bonding by the anti-folates.136
Chloroquine has been a widely used anti-malaria drug for more than 50 years.138 Its anti­
malarial properties were deemed to be perfect, and the emergence of resistance to it led to 
panic. There are many theories to explain the chloroquine resistance but the three 
prevailing possibilities are: i) reduction in the parasite's up-take of the drug; ii) the expulsion 
of the drug from the food vacuole135,136 and iii) mutation of p/CRT (Plasmodium /alciparum 
chloroquine resistance transporter), a transporter in the lysosome,139,140 which is important 
since the action of chloroquine is attributed to its ability to accumulate in the lysosome. The 
first theory is based on the fact that chloroquine is a weak base and when pH levels of thePage 32
lysosome are elevated, the neutral and mono-protonated forms of the drugs are able to 
permeate the membrane and, hence, do not accumulate in the lysosome.141 The second 
relies on an expulsion mechanism, mediated by an ATP-dependent transporter; P- 
glycoprotein, which encodes for the mdr (multi-drug resistance gene), in this case pfmdr, 
which reduces the concentration of chloroquine in the lysosome.136 Finally mutation of 
pfCRT, which facilitates transportation of chloroquine into lysosome, leads to the drug being 
transferred back into the cytoplasm.72
Figure 6. Approximate time-line showing the introduction of anti-malarial drugs (green) and 
the estimated time-span for the parasite to develop resistance to the particular drug or drug 
combination (in red) in the indicated continents.132
Atovaquone, which acts on the electron transfer chain, experienced resistance rapidly when 
it was used as a monotherapy, and is now therefore used in combination with proguanil.114 
Resistance is attributed to: i) mutation in the cytochrome b gene which results in changes in 
the amino acid sequence of the parasite rendering atovaquone ineffective; and ii) the slow 
uptake and high lipophilicity which produces low concentrations of the drug.137
The current first-line treatment for P. falciparum in endemic areas is ACT.142 Resistance to 
the artemisinin-mefloquine combination was recently detected in the Thai-Cambodian 
region in early 2000,143 the same region where resistance to chloroquine was first detected.
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This is of great concern as there are no drugs in reserve which could be used if this 
resistance were to spread, reinforcing the need for the discovery of novel drugs.
1.3. Non-mevalonate pathway
Developing research is now focusing on the apicoplast target, specifically the biosynthesis of 
IPP (isopentenyl pryrophosphate) and DMAPP (dimethylallyl pyrophosphate) through the 
mevalonate pathways or non-mevalonate pathways.144 For a long time, it was believed that 
all living organisms synthesised IPP and DMAPP through the mevalonate pathway.145 It was 
only in 1996 that the non-mevalonate pathway was discovered to produce these 
biosynthetic precursors.145
In high eukaryotes, plants and some bacteria, the mevalonate pathway is responsible for the 
production of: i) farnesyl diphosphate and geranylgeranyl diphosphate which are lipids that 
can be added to proteins for functionality; ii) isopentenyl adenosine which is essential for 
tRNA (transfer RNA) modification; iii) coenzyme Q, an antioxidant that is involved in the 
electron transport chain in mitochondria; iv) dolichol and dolichol-phosphate which are 
necessary in protein glycosylation; and v) the production of an important molecule for bile 
acids and steroid hormones such as cholesterol.146,147 The alternative non-mevalonate 
pathway has been discovered in the chloroplasts of algae, cyanobacteria, eubacteria, both 
gram positive and negative bacteria, and apicomplexan.148 It is the differences in eukaryotic 
and archaeal non-mevalonate pathway (Figure 7) that can be exploited for the selective 
anti-malarial drugs in the inhibition of the P. falciparum.
The malaria parasite, which falls in the apicomplexa category, utilises this alternative 
pathway in the biosynthesis of IPP and DMAPP precursors which produce molecules that 
participate in processes such as protein prenylation, anchoring and degradation, electron 
transfer, regulation of hormones and W-glycosylation,148,149 processes which are essential 
for the survival of the parasite in the human host and vector. The apicoplast, as mentioned 
before, is the plastid in which apicomplexa formation is attributed to cyanobacterial 
endosymbiosis.127,129 The non-mevalonate pathway is of medicinal interest because of its
Page 34
conservation in apicomplexa and absence in the human host. Thus inhibition of the DXOP/ 
MEP (1-deoxy-D-xylulose-5-phosphate) pathway would lead to the development of 
treatments for species such as E.coli, M. tuberculosis and most importantly and specifically 
for this research, P. falciparum. The focus of the current research is specifically on the IPP 
precursor synthesis and, in particular, the enzymes that are involved throughout the 
biosynthetic steps.
1.3.1. Isoprenoid biosynthesis
Isoprenoids are derived from IPP and are a diverse class of natural products.150 They are 
collectively known as terpenes or terpenoids151 and also include steroids and carotenoids.152 
These terpenes make up biologically-important molecules such as vitamins, hormones and 
cytosolic agents.153 There are a large number of enzymes that take part in the synthesis of 
various chemical products and therefore inhibition of these key enzymes will result in 
termination of these processes and finally lead to cell death. The initial research on the 
non-mevalonate pathway was conducted by Rohmer and co-workers in 1999.154 Using 
isotopic-labelled glucose, they traced the formation of hopanoids using NMR (nuclear 
magnetic resonance) data.151,155 The difference between the eukaryotic and archaeal MVA 
pathways led to the target enzymes such as DXR being discovered.
The synthetic pathway begins with the catalysed decarboxylation and condensation of 
pyruvate and D-glyceraldehyde 3-phosphate by, first, the enzyme DXS (1-deoxy-D-xylulose-5- 
phosphate synthase), which requires thiamine diphosphate and Mg2+ or Mn2+ ions152 for 
enzymatic activity, yielding DOXP/ DXP as a product.156 The DXS enzyme is involved in the 
synthesis of vitamins B1 and B6 with an inhibitor being reported for Mycobacterium 
tuberculosis with IC50 value of 10.6 |aM.156
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Figure 7. The eukaryotic and archaeal pathways for the synthesis of IPP and DMAPP; these 
are different in the last 4 steps and this diversity is exploited in the design of anti-malarial
drugs.149
1.3.2. DXR-catalysed mechanism
The second step in the synthesis is the conversion of DXP to MEP (Figure 8) by enzyme DXR 
or IspC which require a co-factor NADPH and a divalent cation such as Mg2+, Mn2 or Co2+ 
ions.156,157 The enzyme DXR uses NADPH as hydride source for intramolecular isomerisation 
and reduction of DXP to MEP.156 This is the target enzyme in the current research as 
crystallographic data is readily available and an opportunity exists for development of
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inhibitors because currently known inhibitors of this pathway are faced with challenges. The 
produced MEP is converted into CDP-ME (4-diphosphocytidyl-2-C-methyl-D-erythritol) by 
the enzyme CTP (cytidine triphosphate) by transfer of the diphosphocytidal group.158 The 
enzyme requires Mg2+ for activity. CTP has been fully characterised as a homo-dimer which 
is potentially druggable by suitable ligands.156 The next step in the synthesis is the 
phosphorylation of CDP-ME to CDP-ME2P by CDP-ME kinase enzyme.154 The enzyme 
transfers the v-phosphoryl group from ATP in the presence of Mg2+ with promising lead 
compounds determined by in silico HTS for this kinase,156 as illustrated in (Figure 8).
The final 2 steps involve the conversion of CDP-ME2P to MECP, a cyclic diphosphate, in the 
presence of Mn2+ and Zn2+ ions156 by monomeric enzyme MECP synthase.148 The final 
reaction, catalysed by MECDP synthase, is the least understood where the cyclised 
diphosphate undergoes reduction followed by elimination which yields IPP148 and, from 
some of the IPP, DMAPP is made.151
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Figure 8. The non-mevalonate biosynthesis of IPP with required enzymes that form the 
catalytic site for reaction, with products essential for the survival of organism. The 
difference in the environment i.e. plastid vs cytosol of synthesis between the pathways is 
essential between the cells.158
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This complex synthesis and cascade of enzymes reveals a large number of potential anti­
malaria drug targets. The majority of known inhibitors are analogues of natural substrates 
therefore a start would be optimisation of properties of these analogues with the optimisim 
that a potent inhibitor can be discovered.
1.4. Target enzyme: DXR
1.4.1. Crystal structure
The target enzyme DXR's crystallographic structure has been determined and illustrated in 
(Figure 9), and this allows computational studies to be conducted readily on the structure as 
well as to deduce data about the active site. The target DXR is the second enzyme in the 
catalytic synthesis of IPP, and it is a critical enzyme for the production of vital molecules that 
the Plasmodium parasite requires. It is therefore important that the DXR structure is fully 
characterised and analysed.
The DXR enzyme is a homo-dimer of 42-45 kD that requires the presence of a divalent 
cation such as Mg2+ and a co-factor NADPH (nicotinamide adenine dinucleotide phosphate) 
for activity.158 The first published crystal structure of the DXR enzyme was the apoenzyme158 
and, since then, many crystal structures have been published and with each further 
understanding of the enzyme has been achieved. The DXR is made up of 3 domains: the 
largest N-terminal domain bind co-factor NADPH comprises of 150 residues160 while the 
small C-terminal domain of 1-150 residues binds natural substrate DOXP.161 These 2 
domains are joined by a linker domain that is 312-398 residues long160 forming a V-shaped 
structure that is flexible to allow the opening and closing of the active site (Figure 9).160,162
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N-terminal
C-terminal
Figure 9. The crystallised structure of FcDXR enzyme (1Q0Q) with co-factor NADPH in each 
of the homo-dimer's binding cavity; contains no ligand bound in the active site; water 
molecules are excluded for clarity. The protein coloured by chain: blue represents subunit A, 
green represents subunit B and the NADPH structure is in ball and stick representation, 
coloured by atom type.163
1.4.2. Binding mechanism
The mechanism of pfDXR begins with the deprotonation of the C-4 hydroxyl group of natural 
ligand DXP which results in bond C3 and C4 to be cleaved producing the enolate of 
hydroxyacetone the presence of Mg2+ stabilises this co-ordination along with glycolaldehyde 
phosphate.164 Then via an aldol reaction a C-C bond is formed between C2 and C4 which 
leads to the production of intermediate 2-methyl-D-erythrose 4-phosphate which is further 
reduced by NADPH yielding the product MEP.165 The (Figure 10) shows the enzymes as well 
as inhibitors that interact in the pathway.
The natural substrate DXP enters the active site and binds to conserved amino acid residues 
Ser199, Ser235, Asn240, Lys241 and Glu244.166 The FcDXR has similar residues. The crystal 
structure of FcDXR, mtDXR and pfDXR with natural substrate DOXP, a known inhibitor 
fosmidomycin and its acetyl derivative FR900098, have been determined. These ligands'Page 39
crystal structures that are readily available bind DOXP analogues which aim to inhibit 
malaria parasite through competitive inhibition with natural substrate. Upon entering the 
binding site, the phosphonate group induces the flexible loop to open, the hydroxamate co­
ordinates to the Mg2+ ion, and groups along the ligand interact with surrounding residues 
through hydrogen bonds, ionic bonds, n-n interactions and various other bonds.167
1.4.3. Known DXR inhibitors
The search for novel drugs with novel modes of action is the focus of many research studies. 
This has been the communication that the WHO has been conveying to all scientists as 
resistance hinders all efforts to eradicate malaria. The discovery of fosmidomycin and its 
acetyl derivative,168 natural antibiotics produced by Streptomyces lavendulae, in the 1970's 
as inhibitors of the DXR enzyme169. They provided the basis for the search of new ligand 
structures with novel modes of action. These antibiotics were evaluated for anti-bacterial 
infections but were abandoned due to limitations.170 These bind to the DXR enzyme 
mimicking the natural substrate, blocking the conversion of DOXP to MEP (Figure 1 0 ).168-169
Figure 10. The non-mevalonate pathway in the production of IPP; fosmidomycin blocks the 
conversion of substrate DXP to product MEP, a vital reaction in this biosynthesis.171
The binding of fosmidomycin in the active site of pfDXR has been extensively studied and 
more analogues have been developed that attempt to enhance activity. Fosmidomycin and 
its acetylated derivative FR900098 were evaluated as potential drugs. However, they had 
limitations such as absorption, recrudescence and half-life.172 Fosmidomycin has also been 
used in combination with Clindamycin, another apicoplast-targeting inhibitor, and these
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show promising results as anti-malarial drugs.169 The potential exists that this combination 
may be a new class of anti-malaria drugs.
Figure 11. The docked structure of enzyme in FcDXR (2EGH) with co-factor NADPH (green), 
known inhibitor fosmidomycin (dark-green) and Mg2+ ion (blue). The water molecules 
excluded for clarity. The dashed lines represent hydrogen bond lengths in A and the 
neighbouring amino acid residues represented by name and ID number.178
The binding mechanism of fosmidomycin (Figure 11) is similar to the DXP substrate. 
Therefore analogues have to contain structural features that are conserved in both DXP and 
inhibitors for activity to be observed. The essential SAR (structure activity relationship) 
contains the particular necessary structural features in the inhibitor for activity to be 
observed.173 The analysis has been conducted by many research studies is illustrated in 
Figure 12 finding that the substitution of the phosphonate head group, which is responsible 
for forming tight hydrogen bonds with various residues as well as the water molecules in the 
DXR binding cavity,174 resulted in no activity. Therefore the phosphonate group is essential 
for binding DXR by increasing the methylene spacer or hydrophobic patch. Reduction in 
activity was observed and thus the two methylene spacer is necessary to permit the 
simultaneous binding of hydroxamate and phosphonate groups. The presence of an electron 
withdrawing group near the phosphonate decreases its pKa which enhances phosphonate- 
DXR interaction. Finally, the use of a pro-drug approach yields good inhibition.174 Page 41
Figure 12. The structure of DXR inhibitor fosmidomycin; essential structural features for 
anti-malaria activity include the phosphonate group (orange), the methylene spacer (green) 
and the hydroxamate moiety (blue). Fosmidomycin drawing constructed using Symyx Draw 
3.2 tools with atom type colour. 175
The indicated SAR, in Figure 12, has been determined to be crucial for activity and therefore 
analogues that will have potential as anti-malaria drugs will require maintaining this SAR, or 
alternatively involve the incorporation of yet-to-be-determined groups that have the ability 
to enhance these properties. For the current research the conserved structures were 
preserved and structural changes that will hopefully enhance activity were introduced.
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1.5. Aims of current studies
1.5.1 Past research
The previous research focused primarily on the exploration of the DXR binding cavity and 
the synthesis of a potential DXR inhibitor.176,177 The series of DXR inhibitors was based on 
fosmidomycin and DOXP analogues which Conibear synthesised, viz., phosphonate esters 
and their phosphonic acid salts, by using heterocyclic amino derivatives which were reacted 
with chloroacetyl chloride or 3-chloropropionyl chloride to produce chloroamides. These 
had minimal inhibitory activities. Furthermore, Mutorwa also synthesised 3-substituted 
anilines using the same route while using different acid chlorides (chloroacetyl chloride, 3- 
chloropropionyl chloride, 4-chlorobutanoyl chloride and 5-chloropentanoyl chloride). These 
compounds provided access to analogues containing 1, 2, 3, and 4 methylene groups in the 
hydrophobic patch (Figure 13).
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Figure 13. Synthesis of phosphonate esters and phosphonic acids.
Another compound series was the synthesis of dihydroxy-amido esters (Figure 14) which are 
mimicking the alkyl backbone of DOXP to retain enzyme-ligand binding specificity and 
modifying the phosphonate and hydroxamate moieties to obtain analogues with improved 
inhibitory activity. The saturation transfer difference NMR (STD) experimental data showed 
that some of the dihydroxy-amido phosphonic acid derivatives bind to FcDXR, whilst others 
did not; however, these compounds were not tested using FcDXR or PfDXR bioassays.Page 43
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Figure 14. Synthetic routes explored in the synthesis of the dihydroxy-amido 
phosphonate esters and their corresponding acid derivatives.
1.5.2 Current research
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Figure 15. Reported and proposed W-benzylated fosmidomycin analogues.
Further quantities of the W-benzyl-substituted phosphoramidic acids 34a-f (Figure 15), 
obtained via this 9-step pathway outlined in Figure 16, these were required for bioassay
purposes. Moreover, since Haemers et al.194 observed that the introduction of a 3,4- 
dichlorobenzyl moiety, in the DXR inhibitors which they were researching, increased 
inhibition activity significantly, we decided that it would be useful to prepare the 3,4- 
dichlorobenzyl analogue of our series of potential DXR inhibitors 34a-f. We also considered 
that introduction of the strongly electronegative 3-nitrobenzyl moiety might prove to be
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worthwhile. Here the introduction of the dichlorobenzyl derivative showed increased 
inhibition. The nitrobenzyl derivative is deactivating and therefore it is interesting to 
observe the effects of its presence in the effect on inhibition.
t'
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b C H 2-O H H
c N H 2 H
d S H H
e N O 2 H
f C l C l
Figure 16. The synthetic pathway of the W-benzyl derivatives.
Access to the furan derivatives (Figure 17), as conformationally constrained fosmidomycin 
analogues has already been developed in our group, but the conformation of the 
regioselectivity of the second step (acylation of the O-tritylated intermediate 36) was 
required. Regiosiomers are obtained in these reactions and the structures drawn in Figure 
16 represent what we expect the favoured products to be (37a, 37b, 37c).
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Figure 17. Furan derivatives with varying R groups, showing the expected regioisomer (a-c), 
in each case.
The aims of this research project have thus included the following.
potential ligands in the PfDXR active site.
2. The preparation of further quantities of the W-benzylated phosphoramidic acids 34a- 
d, for bioassay purposes, via the established 9-step pathway.
3. An extension of this method to access the novel 3,4-dichloro- and 3-nitrobenzyl 
analogues 34e and 34f.
4. A repetition of the acylation of the O-tritylated intermediate 36 to establish the 
regioselectivity of the acylation in each case (for R = H, CH3, t-butyl).
1. A detailed and extensive computer-modelling analysis of the docking of a range of
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2. Discussion
2.1. Molecular modelling
Docking simulations were performed in order to explore the DXR enzyme binding site in 
order to predict the binding affinity of the generated ligands and to identify and evaluate 
hydrophobic binding regions. The enzyme receptor pocket may be exploited by the 
introduction of large hydrophobic groups for increased binding and inhibition. This 
investigation was conducted as an extension of previous work on examining the P/-DXR 
binding cavity.176 The research aimed to assess the limitations and properties that 
determine effective binding of the ligands in the active site.
Docking studies were conducted using a series of 63 structures modelled on fosmidomycin
173
analogues. The 63 ligands were constructed using Discovery Studio Visualizer 4.0, while 
the enzyme structures were obtained from the protein data bank. Six protein x-ray crystal 
structures were found to contain the natural ligand DXP with fosmidomycin or FR900098
163
in their binding cavity. To validate the reliability of the docking study, the natural ligand 
DXP and the known inhibitors, fosmidomycin and FR900098, were removed from the 
binding site and re-docked along with the constructed putative ligands shown in (Figure 
18).
Figure 18. The variation of substituents in the modelled ligands, where n= 2, 3 or 4, R1= [a]: 
CH3, [b]: CH2CH3 or [c]: CH2OH and R2= H, CH2Br, SH, OH, NH2, amongst others.
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Table 1. Summary of the ligands constructed in silico; n is the number of methylene 
groups in the spacer chain, while the variations in the terminal carbonyl group and 
the benzyl substituents are indicated by R1 and R2, respectively.
Ligand n R1 R2 n R1 R2 n R1 R2
2a_H 2 CH 3 H 3a_SH 3 CH3 SH 4a_OH 4 CH 3 CH 2OH
2a_SH 2 CH 3 SH 3a_OH 3 CH3 CH 2 OH 4a_Cl 4 CH 3 Cl
2a_OH 2 CH 3 CH 2OH 3a_Cl 3 CH3 Cl 4a_Br 4 CH 3 CH 2 Br
2a_Cl 2 CH 3 Cl 3a_Br 3 CH3 CH 2 Br 4a_CH3 4 CH 3 CH 2CH 3
2a_Br 2 CH 3 CH 2 Br 3a_CH3 3 CH3 CH 2 CH3 4a_N H 2 4 CH 3 NH2
2a_CH3 2 CH 3 CH 2CH 3 3a_N H 2 3 CH3 NH2 4b_H 4 CH 2 CH 3 H
2a_N H 2 2 CH 3 NH2 3b_H 3 CH 2 CH 3 H 4b_SH 4 CH 2 CH 3 SH
2b_H 2 CH 2 CH 3 H 3b_SH 3 CH 2 CH 3 SH 4b_OH 4 CH 2 CH 3 CH 2OH
2b_SH 2 CH 2 CH 3 SH 3b_OH 3 CH 2 CH 3 CH 2 OH 4b_Cl 4 CH 2 CH 3 Cl
2b_OH 2 CH 2 CH 3 CH 2OH 3b_Cl 3 CH 2 CH 3 Cl 4b_Br 4 CH 2 CH 3 CH 2 Br
2b_Cl 2 CH 2 CH 3 Cl 3b_Br 3 CH 2 CH 3 CH 2 Br 4b_CH3 4 CH 2 CH 3 CH 2CH 3
2b_Br 2 CH 2 CH 3 CH 2 Br 3b_CH3 3 CH 2 CH 3 CH 2 CH3 4b_N H 2 4 CH 2 CH 3 NH2
2b_CH3 2 CH 2 CH 3 CH 2CH 3 3b_N H 2 3 CH 2 CH 3 NH2 4c_H 4 CH 2 OH H
2b_N H 2 2 CH 2 CH 3 NH2 3c_H 3 CH 2 OH H 4c_SH 4 CH 2 OH SH
2c_H 2 CH 2 OH H 3c_SH 3 CH 2 OH SH 4c_OH 4 CH 2 OH CH 2OH
2c_SH 2 CH 2 OH SH 3c_OH 3 CH 2 OH CH 2 OH 4c_Cl 4 CH 2 OH Cl
2c_OH 2 CH 2 OH CH 2OH 3c_Cl 3 CH 2 OH Cl 4c_Br 4 CH 2 OH CH 2 Br
2c_Cl 2 CH 2 OH Cl 3c_Br 3 CH 2 OH CH 2 Br 4c_CH3 4 CH 2 OH CH 2CH 3
2c_Br 2 CH 2 OH CH 2 Br 3c_CH3 3 CH 2 OH CH 2 CH3 4c_NH 2 4 CH 2 OH NH2
2c_CH3 2 CH 2 OH CH 2CH 3 3c_NH 2 3 CH 2 OH NH2
2c_NH 2 2 CH 2 OH NH2 4a_H 4 CH3 H
3a_H 3 CH 3 H 4a_SH 4 CH3 SH
The 63 ligands, summarised in Table 1 and illustrated in Figure 18 differ in: i) the number of 
methylene groups (CH2)present [ (CH2)n: n= 1, 2, or 3]; ii) the nature of the terminal metal­
chelating group [Rx= a (CH3); b (CH2CH3) or c (CH2OH) and iii) the nature of the benzyl 
substituent (R2= CH2Br, NH2, OH, SH etc.). Thus for ligand 2a_Br (Figure 19), n = 2, Rx= CH3 
and R2= Br. Page 48
The constructed ligands retain the polar phosphonate moiety, which is present in both 
fosmidomycin and FR900098 and which is important for hydrogen bonding to nearby amino 
acid residues, and the polar hydroxamate group which is essential for coordinating to the 
metal cation.
Figure 19. Structure of ligand 2a_Br in which n = 2, R ^ C H  and R2=Br with water molecules, 
the crystal structure of ligand 2a_Br is shown stick representation with atom-type colour.178
The six Pf- or E.Coli- DXR protein structures which were used are; 1Q0L, 1Q0Q, 2EGH, 3AU8, 
3AU9 and 3AUA which are from Pf and E.coli species. The DXR protein 1Q0L (Figure 20) is a 
EcDXR protein with the known inhibitor fosmidomycin bound in the active site; 1Q0Q is a 
selenomethionine-labelled protein from E.coli which contains the natural substrate DXP 
bound in the active site; 2EGH from E.coli has no ligand; 3AU8 is another PfDXR protein with 
a bound fosmidomycin ligand; 3AU9 is PfDXR protein with bound fosmidomycin in the active 
site and 3AUA is a Pf DXR protein and has FR900098 bound in the active site. All of these 
structures contain the NADPH co-factor and the divalent metal cation Mg2+, and were 
completely desolvated (2 water molecules on the polar phosphonate moiety of ligands was 
included in the docking process) prior to docking/modelling studies.
Each sub-unit of the DXR 86-kDa homodimer consists of a large N-terminal NADPH-binding 
domain (77 -  230 amino acid residues) adjacent to a large catalytic domain (231 -  269 
amino acid residues) which provides the groups necessary for catalysis (metal + substrate 
binding). This catalytic domain is connected to a small C-terminal domain (396 -  486 amino 
acid residues) with a linker region (370 -  395 amino acid residues) which constitutes a
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flexible 'lid' that closes the active site once a substrate is bound. For the purpose of the 
current docking simulations, the sub-unit A binding site was used as the docking site with 
both NADPH molecules in the same orientation. The 63 ligand variations along with the 6 
protein structures (Figure 20) and 3 known ligands (DOXP, fosmidomycin and FR9000098) 
made up the collection for molecular modelling in this docking study.
Figure 20. The structure of Pf DXR protein subunit A from 1Q0L with NADPH co-ordinated in 
the active site. The protein is coloured by secondary structure type with ligand NADPH in 
ball and stick with atom-type colours.163
The docking of the phosphoramidate derivatives began with the removal of the solvating 
water molecules that are present in the crystal structures of the proteins as well as the 
removal of the bound substrate i.e. fosmidomycin, FR9000000 or DOXP. The NADPH as well 
as the divalent Mn2+ cation were left in at their original positions. The +2 charge was 
manually assigned to the manganese and the two water molecules that are normally 
coordinated to the bound phosphonate group in fosmidomycin were added near the 
phosphonate groups of each of the ligands, thus facilitating evaluation of the correct 
alignment or orientation of the docked ligand in the active site. To validate the reliability of 
the docking study, the natural ligand DXOP and the known inhibitors fosmidomycin and 
FR900098 were removed from the binding site, their dihydrated structures were optimised 
and they were successfully re-docked. The structures of the 63 dihydrated model ligands
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were similarly optimised and docked into the various enzymes. The best docking 
conformation, in each case, was then analysed and selected, based on the binding affinity, 
calculated from the binding free energy of each atom in the ligand -  an indication of the fit 
of the ligand in the active site. The docked ligands were then overlaid with other docked 
ligands to allow for meaningful comparison of ligand and receptor cavity.
For each of the protein models, certain residues within the active site were assigned as 
flexible. This permits dynamic movement within the active site to reproduce the flexibility 
that the protein might exhibit in vivo. The same residues, although numbered differently 
(there are variations in the residue number due to the protein sequence and numbering 
system differences) in the X-ray structures were chosen to be flexible in docking to the six 
crystal structures. These residues correspond in all six proteins and are in direct proximity to 
the active site. For the 2EGH protein, Ser 221, Ser 185, Asn 226, Lys 227 and Glu 230 were 
the flexible residues, for 1Q0Q and 1Q0L, these were Ser 222, Ser 151, Asn 227, Lys 228 and 
Glu 231, while for proteins 3AU8, 3AU9 and 3AUA the same residues, Ser 270, Ser 306, Asn 
361, Lys 312 and Glu 315 were selected as flexible. These flexible residues within the active 
site were chosen since they correspond in all 6 proteins with slight differences in the residue 
number in the various DXR crystal structures.
Using Windows Secure Copy (WinSCP),179 the constructed ligands and the unbound, 
desolvated protein were transferred to a linux cluster. WinSCP, free software available 
programme readily from the internet created by Martin Prikryl in 2000,179 is used to transfer 
data from a personal computer to a remote computer -  commonly a supercomputer that 
will process the data. A terminal (putty) was used to control and access the submission 
scripts on the cluster while Autodock Vina,180 an open-source program was used for the 
docking simulations of the constructed ligands and modified proteins. The ligands and 
protein were prepared using Autodock tools; Autodock Vina has proved to be significantly 
more accurate in the prediction of binding affinity as well as exhibiting other features, such 
as ease of use, speed and assignment of flexible side chains.180 The anhydrous and 
dihydrated ligands were used in docking studies conducted.
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Docking in the active site was first evaluated for EcDXR enzyme, using the 1Q0L168 enzyme 
structure which contains fosmidomycin, NADPH and the Mg2+ cation (Figure 21). Each of the 
63 ligands were evaluated for:- i) their ability to bind to the active site; ii) the accuracy of 
their alignment with fosmidomycin and, finally iii) their binding orientation relative to 
fosmidomycin. These aspects were considered to be important in identifying the inhibition 
potential of the various ligands. Ligands with active site interactions similar to that of 
fosmidomycin are expected to have similar binding abilities, possibly with enhanced 
penetration of the active site and increased inhibition. The orientation of the designed 
ligands in comparison to fosmidomycin is essential as the critical ligand moieties need to 
align with the appropriate amino acid residues to accommodate binding in the active site. 
This does not preclude other binding interactions from being involved but ensures the 
conservation of established interactions.
The two connected binding pockets in the protein active site should be occupied by the co­
factor NADPH, the Mg2+ cation and the docked ligand. Fosmidomycin and 25 of the 63 
ligands appear to occupy the same binding pocket (Figure 21). However, only 17 of these 
ligands were both correctly docked and well orientated and, of these, only those ligands 
whose binding energy was also favourable will be evaluated further in detail. A general 
trend with 1Q0L was an increase in the length of the methylene spacer (n=3-4) led to 
ligands being extended beyond the active site although some exceptions were encountered 
when R2 groups were small (e.g H, SH and NH2) but when R2 = CHsBr or CH3, the ligand was 
actually excluded from the binding site. The presence of the terminal ethyl group such as 
n=2 and R2 = SH resulted in SH (and in some cases NH2) being retained in the active site. 
When the terminal group was the hydroxymethyl moiety, the ligand remained in the active 
site when R2 was SH, NH2 and H.
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Figure 21. FcDXR Protein 1Q0L subunit A showing the distribution of 63 modelled ligands; 
majority of the ligands cluster outside the binding cavity of the enzyme, some near NAPDH 
while the rest excluded from the active site cavity. The cartoon of the protein is coloured 
using a rainbow type format with ligands and NADPH in ball and stick format with atom type 
colour.178
The docked ligand 2a_H (Figure 22) interacts mainly with the DXR active site, the 
phosphonate group interacts with Lys228 and is bound to water molecule hydrating the 
active site, the dihydrogen groups interact with Asn227, Ser186, Ser222 and the water 
molecules, the hydroxide interacts with Met214, the terminal carboxylic groups interacts 
with Ser151 with methyl binding to Trp212. The additional interactions are the aromatic ring 
electrons interacting with Trp212, Glu152 and Lys228. The known inhibitor fosmidomycin 
(yellow) is included as a comparison for conformation and orientation in the active site. The 
added groups give rise to the new interactions observed with fosmidomycin. The same 
interactions as the 2a_H are observed for 2a_Cl with the additional chlorine interaction with 
His251 and Ser254. This was seen for 2a_NH2 and 2a_SH as well (where this interaction is 
now with the NH2 or the SH). This was promising as the addition of the phenyl R groups did 
not exclude the ligands from binding to the active site but further enhanced the interaction 
of the ligand with the conserved amino acids as well as introducing new interactions.
Page 53
Figure 22. The ligand 2a_H interacts in the FcDXR active site (1Q0L) with the conserved 
amino acids that are observed with fosmidomycin with additional interactions with the 
auxiliary groups that the analogues contain and 2 water molecules. The crystal structure of 
fosmidomycin and 1a_H are in ball and stick with atom-type colour. The hydrogen atoms are 
not shown and dashed lines represent H-bond distance in A.178
The next aspect explored was the substitution of the terminal methyl on the ligand with an 
ethyl group to evaluate the change of geometry of docking as a result of increasing the size 
of the terminal group while keeping the methylene spacer the same. The addition of this 
ethyl terminal group resulted in all ligands excluding 2b_H and 2b_SH preferring to bind 
outside the active site as well as resulted in 2b_H "reverse" binding relative to 
fosmidomycin. In the best docking conformation, the terminal ethyl group interacted with 
amino acids that originally were proximal to the phosphonate group in fosmidomycin and 
vice versa. The ligands exhibiting "normal" binding were analysed as these interactions 
proved favourable for fosmidomycin and therefore potential analogues should aim to 
secure binding similar to that of a known inhibitor.
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The ligand 2b_SH (Figure 23), has all the interactions which are observed in the methyl 
analogue but with further interaction between the terminal ethyl group and Trp212. The R 
group SH has further interactions with IIe256 and Thr184. Fosmidomycin (yellow) compares 
favourably with ligand 2b_SH in both interactions and orientation.
Figure 23. Docked conformation of ligand 2b_SH in the FcDXR active site (1Q0L) showing 
interacting residues. The crystal structure of fosmidomycin structure in ball and stick format 
in yellow, while 2b_SH has atom-type colour.178
This large terminal group was further investigated by the addition of a terminal 
hydroxymethyl (c), while keeping the methylene spacer length constant. For this series of 
terminal hydroxymethyl models, only 2c_SH was retained in the active site during docking; 
all other ligands docked external to the active site. The presence of the terminal 
hydroxymethyl group (c) resulted in unique orientation and interaction of the 2c_SH ligand 
with Trp212 and the co-factor NADPH. These interactions have not been observed with any 
of the ligands, and their presence is interesting for how far the ligand is able to interact 
directly with NADPH and potential for synthesis of a ligand bound to NADPH analogues that
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might enhance binding in both binding domains and activity. In this binding there is an 
apparent reversal of the roles of the aromatic and hydroxylamine portions of the ligands, 
with the aromatic side orienting toward the NADPH while the hydroxylamine portion (with 
the terminal hydroxymethyl group) occupying the lower pocket.
Figure 24. Docked conformation of ligand 4c_SH in the in the FcDXR active site (1Q0L), with 
expected interactions with proximate residues. The crystal structure of fosmidomycin 
structure in broader stick representation with atom-type colour.178
Finally, increasing the methylene spacer from 2 to 3 methylene groups resulted in exclusion 
of R2 (such as OH, CH3 and Br) in the binding site as well as the presence of the larger 
terminal ethyl (b) and hydroxymethyl (c). However, this increase in the methylene spacer 
length did not affect NH2 and SH interaction in the active site for the appropriate 
compounds. The ligands 2a_CH3, 2a_Cl and 2a_H bound directly on top of NADPH while 
ligands 2b_SH, 2c_SH, 2a_NH, 2b_NH, 2c_NH and 2a_Cl were the only models that docked 
in the correct conformation and orientation as fosmidomycin. When the methylene spacer 
was increased yet again to 4 methylene groups while keeping orientation and substitution 
constant, this resulted in the majority of the ligands not binding in the DXR active site with
Page 56
the exception of 4a_NH, 4b_H, 4c_H and 4c_SH. These ligands, when in the binding site, 
align the phenyl group along with fosmidomycin (yellow) and the long methylene chain 
occupies a different pocket in the active site (Figure 24). This explores different binding 
during docking, and these interactions with additional pockets could potentially provide 
novel leads.
The FcDXR enzyme 1Q0Q is a selenomethionine-labelled DXR protein from E.coli with 
natural substrate DOXP bound in the active site. The protein crystal structure is a 
homodimer and thus subunit A was used for docking studies. This protein is the same 
protein as 1Q0L but with a different template ligand in the active site and therefore the 
interaction of the ligands should be similar to that of 1Q0L but the binding interactions are 
compared to DOXP and exceptions will be reported.
Figure 25. Protein 1Q0Q subunit A showing the distribution of 63 ligands; the majority of 
the ligands fall outside the binding cavity/site of the enzyme. The protein colour by 
secondary type with ligands and NADPH in ball and stick with atom-type colour.178
The DOXP and 17 of the 63 ligands appear to be in the same binding pocket (Figure 25). The 
ligands that were both correctly docked and well orientated, i.e. where the phosphonate 
group orientated similarly to DOXP, were only 9. The ligands bind in two conformations, 
2a_OH, 2b_NH, 2b_OH, 2c_Cl, 2c_NH and 2a_NH had the phenyl group aligned with DOXP 
while the orientation of 2a_H, 2a_NH, 2a_SH, 2b_H, 2b_SH, 2c_OH, 2c_SH, 4a_H and 4c_NHPage 57
was identical to that of DOXP. Evidently the large R2 group as well as the majority of the 
increased methylene spacer (2-3) and large terminal groups (b-c) contributed to exclusion 
from the active site.
Lys227
Figure 26. The ligand 2c_OH interacts in the FcDXR active site (1Q0Q). The crystal structure 
of 2c_OH and DOXP are in ball and stick with atom type colour with Mg2+ ion (blue). The 
hydrogen atoms are not shown and dashed lines represent H-bond distance in A.178
In Figure 26, ligand 2c_OH shows interactions in the DXR active site via the phosphonate 
group interacting with Ser221 and is also bound to a water molecule hydrating the active 
site. The hydroxyl group on the phosphate moiety interacts with Asn226, Lys227 and the 
water molecules. The hydroxide interacts with Trp211 and Met218, and the phenyl hydroxyl 
group interacts with residue Arg207. The additional interactions are the aromatic ring 
electrons interacting with Ser185, Ser221 and Met218.
Docking in the active site was then evaluated for the PfDXR enzyme; the remaining proteins, 
3AU8, 3AU9 and 3AUA are all DXR crystal structures from P. falciparum. 3AU8 has no
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inhibitor such as fosmidomycin and FR9000089 in the active site. All the structures contain a 
divalent cation and NADPH, and docking to this enzyme was mainly to study the interactions 
of the potential ligands in this PfDXR. The reproducibility of binding for the 3AU8 under the 
docking method used could not be ascertained for validation due to this absence of a ligand 
in the crystal structure. However, the docking proceeded under the conditions described 
earlier which were validated. In Figure 27, the distribution of the ligands are compared 
between the proteins 3AU9 and 3AUA. It is therefore essential for docking studies to 
include a known ligand template. From 3AU9 it was observed that only 5 ligands appear in 
the active site in the correct orientation as the crystal structure fosmidomycin while for 
3AUA there are 12 ligands that align with FR9000089.
Figure 27. Proteins 3AU9 and 3AUA subunit A showing the distribution of 63 ligands; the 
majority of the ligands fall outside the binding cavity/site of the enzyme for 3AU9 and 
3AUA. The protein colour is by rainbow format and the structure with ligands and NADPH in 
stick representation with atom-type colour.178
Figures 28 and 29 details the results of docking one ligand; the interaction of 2a_NH is 
analysed as docked in both proteins (3AU9 and 3AUA) against fosmidomycin and FR900089 
respectively. As illustrated, the ligand (2a_NH) interacts with the same residues in both 
proteins and is oriented along with the template ligands (yellow). The ligand 2a_NH exhibitsPage 59
a "reverse" binding relative to fosmidomycin. The terminal carboxylic group is interacting 
with amino acids that interacted with phosphonate group in fosmidomycin. The compound 
has some inhibition of 82.11 nM, as per Ki value, which indicated that, although they bind 
differently to fosmidomycin, they have the potential to be inhibitors, which can be further 
researched. The ligands exhibiting "normal" binding were further analysed as these 
interactions are by the original design for specificity of this series of ligands. Since these 
interactions match those observed for a ligand with good binding and specificity, viz 
fosmidomycin, the potential analogues should aim to secure binding in a similar manner.
Figure 28. The protein 3AU9 DXR crystal structure with ligands in the active site; 2a_NH and 
fosmidomycin (yellow) are in ball and stick with atom-type colour. The hydrogen atoms are 
not shown and dashed lines represent all interactions in distance in A.178
Several other ligands also interact in docking with the active site residues in much the same 
way. The main difference is however that certain groups such as the terminal 
hydroxymethyl (b) or OH R group introduce further interactions with residues. The terminal
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hydroxymethyl (b) was retained in the active site for smaller R groups regardless of 
methylene spacer length. Both Figures 28 and 29 reiterate how essential the template 
ligand is for the evaluation of potential ligands as the orientation and conformation is vital 
for the formation of known interactions.
Figure 29. The protein 3AUA DXR crystal structure with ligands in the active site; 2a_NH and 
FR9000089 (yellow) are in ball and stick with atom type colour. The hydrogen atoms are not 
shown and dashed lines represent all interactions in distance in A.178
A comparison of the calculated Ki values reveals some interesting information (Table 2). The 
inhibition constant (Ki) is the concentration of the inhibitor necessary for reducing the rate 
of the enzyme activity by half. This analysis was conducted to determine the various 
changes in the theoretical Ki that are observed for each of the proteins when the ligands 
were varied. The results which can be inferred from this data is that certain changes in R 
groups (R1 or R2) affect Ki and hence potentially exhibit inhibition.
Determining the Ki experimentally, although more accurate, can be time-consuming and 
tedious and thus, more frequently, theoretical calculations of inhibition constants are 
conducted. The calculations involve the plotting of fractional enzyme activity in thePage 61
presence of an inhibitor as a function of a constant enzyme and inhibitor concentration.186 
These values compare well with experimental values (on test cases that were used to 
calibrate the software) and therefore can be a good indicator of potentially potent 
inhibitors. In Figure 30 are the average Ki values (pM) for each protein is represented in a 
graph. The experimentally (computationally) acquired Ki values for fosmidomycin and 
FR900098 are 0.251 pM and 0.101 pM respectively, 187 therefore values closer or less than 
these show potential as lead compounds.
Table 2. The average Ki values and standard deviations for docked ligands for each of the six 
proteins.
Protein Mean Ki (pM) Ki St Dev (pM)
1Q0Lp 34,78 85,68
1Q0Qp 10,75 20,44
2EGHp 0,1539 0,6649
3AU9p 29,23 125,40
3AUAp 23,29 120,70
Mean Ki value per protein
3AUAp 
2EGHp
+■* o
£  1Q0Lp
0 10 20 30 40
Average Ki valu e  per protein (pM )
Figure 30. The average Ki values (pM) across the FcDXR and PfDXR protein.
The protein with the lowest average Ki is 2EGH at 0.15 pM, while proteins 3AUA, 3AU9, 
1Q0Q and 1Q0L have average Ki of 23.29, 29.23, 10.75 and 34.24 pM, respectively. Another 
analysis was of the average Ki value as the methylene spacer increases (Table 3 and Figure 
31) for each of the ligands. The expectation is that the longer the methylene spacer (2-4),
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the higher the average Ki. However, due to the effect of phenyl group interactions aligning 
with the template ligand and allowing the rest of the chain to occupy a different pocket as 
well as the terminal hydroxymethyl (c) forming additional interactions in the protein cavity, 
the Ki values vary for each protein.
Table 3. The average Ki value for each of the proteins by length of methylene spacer i.e. 2-4 
methylene groups in chain.
Ki mean per chain length (pM) 1Q0Lp 1Q0Qp 2EGHp 3AU9p 3AUAp
2 59,7581215 14,85521 0,132197 0,039902 34,13813
3 24,1891424 11,87607 0,049761 65,15088 34,60815
4 20,9232165 5,241746 0,285917 22,1587 0,030747
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Figure 31. The average Ki values (pM) across the FcDXR and PfDXR protein as the length of 
the methylene spacer increases.
The studies conducted were to evaluate the binding site of FcDXR and PfDXR by using 
known inhibitors, fosmidomycin and analogues, to analyse and assess the active site by 
varying the chain length of the methylene spacer, changing the terminal group and 
introducing various W-benzyl derivatives. The results indicated that although exceptions 
occur in all cases, i) the two methylene spacer group proved vital for accurate orientation 
and conformational interactions to occur in the binding cavity, ii) the change of methyl
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terminal group to ethyl led to the majority of ligands being excluded from the binding site 
while the hydroxymethyl resulted, unexpectedly to mostly "reversed" binding as well as 
formation of further interactions with its hydroxyl group, and iii) The majority of the smaller 
R groups allowed ligands to bind in the active site, in some instances, irrespective of chain 
length and terminal group while the larger R group hindered the ligand entrance into active 
site.
The analysis of the theoretical Ki values calculated confirms the molecular modelling data. 
The enzyme-ligand relationship in these docking studies is not straight forward. The 
presence of certain groups enables better binding and interaction even when factors that 
are supposed to exclude these exist. It is therefore important that further analysis of this 
data is conducted so that trends based on all factors are determined which could lead to 
novel "reverse" fosmidomycin-based lead compound and the inclusion of more terminal 
groups that contain interacting groups such as the hydroxymethyl.
Analysis of the docking studies resulted in 2a_H, 2a_OH, 2a_SH, 2a_NH2, 2a_Cl and an 
additional 2a_NO2 to be taken further into synthesis. The synthesis kept the R1 group 
constant as well as the methylene spacer while varying R2. The 3-nitrobenzyl in the a-aryl- 
substituent was introduced in order to evaluate the effect of a strongly electron 
withdrawing group effect on electron density. The dichloride substituted analogues were 
found to be high in inhibition193 and thus 2a_Cl was synthesised as a dichlorobenzyl 
compound. 2a_H had a calculated average Ki of 1.16 |iM across all 5 proteins, 2a_OH had 
0.42 |iM, 2a_SH had 0.18 |iM, 2a_NH2 had 3.65 |iM and 2a_Cl had 8.97 |iM.
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2.2. Synthesis of W-benzyl substituted phosphoramidates
2.2.1. W-Benzyl substituted phosphoramidate derivatives
The FcDXR and PfDXR crystal structure docking studies with the known inhibitor 
fosmidomycin and DXP revealed critical amino acid residues in the active site of DXR that 
are essential for effective binding as well as inhibition in the case of fosmidomycin. Docking 
studies have illustrated the presence of three additional binding pockets,176 which we 
exploit in the synthesis of novel lead compounds. The previous research groups introduced 
the a-aryl-substituent which according to docking studies occupies the newly identified 
pockets thus strengthening the binding and providing bases for increased inhibition.
The structure-activity studies of fosmidomycin and FR9000089 revealed the importance of 
the tri-methylene spacer, the phosphonate group and a metal binding moiety such as 
nitrogen or oxygen groups in the potential ligands. This was also observed during the 
molecular modelling of the W-benzyl substituted phosphoramidate derivatives, where the 
increase in the length of the hydrophobic patch reduced entry into binding site and oxygen 
and nitrogen groups were seen co-ordinating to the divalent metal cation in the DXR active 
site. The W-benzyl substituted phosphoramidate derivatives 34a-f are fosmidomycin 
analogues which conserve the essential phosphonate and hydroxamate functional groups in 
fosmidomycin but include the substituted benzyl group designed to occupy an additional 
binding pocket.
In this section, attention is focused on the multi-step synthesis of such compounds (34a-f; 
Scheme 1). Some of the compounds have been prepared previously176,177 but additional 
material was required for bioassay purposes; others (34e-f) are new. These latter 
compounds contain the 3-nitrobenzyl group as the a-aryl-substituent to permit evaluation 
of the effect of a strongly electron-withdrawing group on the electron density and binding 
of the phosphonate, since 3,4-dichlorobenzyl analogues scaffolds have been shown to 
increase inhibition of PfDXR.193
Page 65
o- o
^  0
v ° 0 - l
' ° " Nn h 2 r d  H
2 5 2 6
O—P— N ,  o -
*  Sr
2 7
0 - P —NH IAr
2 8
R 1 R 2
a H H
b C H 2-O H H
c N H 2 H
d S H H
e N O 2 H
f C l C l
Scheme 1. Synthesis of W-benzyl substituted phosphoramidic derivatives.
Reagents and conditions; i) Hexamethyldisilizane, benzene, 800C ii) NaH, benzene, rt, 
bromoacetaldehyde diethyl acetal, TBAB, 800C, 4 h iii) EtOH, 800C, 1h iv) NaH, THF, benzyl 
halide, rt, 24 h v) 2M HCl, rt, 24 h vi) O-benzylhydroxylamine, MeOH, 400C, 3 h then 
NaBHsCN, MeOH, conc. HCl, 1 h, NaBH3CN, 1 h vii) acetyl chloride, triethylamine, DCM, 00C, 
N2, 24 h viii) Pd/c, dry MeOH, H2, 18 h then ix) TMSBr, DCM, 00C, DCM, H2O, 24 h.
The first three steps in the synthesis of W-benzyl substituted phosphoramidic derivatives 25­
28 are illustrated in scheme 2. Using a method reported by Zwierzak et al.,193 diethyl 
phosphoramidate 25 was converted into the silylated derivative 26 in 98 % yield. The 
silylated amine was then deprotonated using sodium hydride and reacted with 
bromoacetaldehyde diethyl acetal; removal of the TMS group was effected in the presence 
of the catalyst (TBAB) in ethanol to afford the intermediate 28 in 92 % yield.
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Scheme 2. The protection of diethyl phosphoramidate during the preparation of the diethyl 
acetal.
Reagents and conditions: i) Hexamethyldisilizane, benzene, 800C ii) NaH, benzene, rt, 
bromoacetaldehyde diethyl acetal, TBAB, 800C, 4 h iii) EtOH, 800C, 1h.
Figure 32 illustrates the *H NMR spectrum of the silylated derivative 26 with the silyl methyl 
groups resonating as a 9 proton singlet at 0.10 ppm, the methyl and methylene protons of 
diethyl acetal moiety resonating at 1.20 ppm and 3.91 ppm, respectively and the amine 
proton at 2.72 ppm. This product was found to be highly hygroscopic, and therefore needed 
to be taken immediately to the next step or stored in an air-tight container.
3 x Si-CH3 2
2 x CH3
Figure 32. 600 MHz *H NMR spectrum of compound 26 in CDCl3.
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In the 13C NMR spectrum of compound 28 (Figure 33), the phosphonate and acetal methyl 
carbons resonate at ca. 15 ppm, the amide methylene carbon at 31 ppm, the diethyl ether 
methylene carbons at 65.25 ppm and the phosphonate ester methylene carbons at 102 
ppm.
T nr yNH2 NH2
40 41
Br
41a
SH
OH
42
Scheme 3. Preparation of amino and mercapto benzyl halides.
Reagents and conditions: i) PBr3, DCM, 00C, 1 h then rt 25 h ii) H2O, HCl, NaNO2, Na2S2, 00, 1 h 
iii) NaBH4, 00 then rt, 1h.
In the next step in Scheme 1, (step iv), the synthesis involves the introduction of the various 
benzyl substituents to afford the tertiary phosphoramides 29a-f. The benzyl halides of 29c-d 
were not commercially available and were therefore synthesised according to Scheme 3. 
The synthesis of 3-aminobenzyl bromide 41 involved the reaction of 3-aminobenzyl alcohol 
with phosphorous tribromide; subsequent treatment of the white product with 1 equivalent 
of potassium hydroxide afforded compound 41 in 77 % yield. Compound 41 was in turn used 
in the synthesis of 42; thus 3-aminobenzyl bromide 41 was reacted with sodium nitrite 
resulting in a diazonium salt which was treated with sodium disulphide to produce a 
disulphide intermediate 41a which was then reduced using sodium borohydride in THF to 
yield the 3-mercaptobenzyl bromide in 65% yield. The percent yields obtained from Scheme 
1 are shown in Table 4.
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Table 4. Percentage yields obtained for the synthesis of W-benzyl phosphoramidate 
derivatives 25-29 (a-f) in the synthetic route Scheme 1.
Ar-R Percentage yie ld  (%)
2 98
4 92
5a 57
5b 35
5c 50
5d 65
5e 20
5f 31
Figures 34 and 35 illustrate the *H NMR spectra of compounds 41 and 42, respectively. In 
Figure 34, the amine protons are observed to resonate at ca. 5 ppm, the methylene protons 
at 4.35 ppm and the four aromatic protons between 6 and 7 ppm. Figure 35 illustrates the 
mercapto proton signal at 3.65 ppm, the methylene signal at 4.61 ppm and the four 
aromatic proton signals resonate in the range 6.60 -  7.22 pp
T TT t  1
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Figure 34. 600 MHz *H NMR spectrum of compound 41 in DMSO-d6.
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Figure 35. 600 MHz *H NMR spectrum of compound 42 in CDCl3.
In the next step (step iv) of the synthesis the various benzyl halides were attached to thye 
nitrogen of the phosphoramidate moiety. The introduction of an W-benzyl group, rather 
than a W-benzyl group, was done to avoid generating a chiral centre and consequent 
problems with asymmetry. The NH group in compound 28 was deprotonated with sodium 
hydride then reacted with the corresponding benzyl halides 29a-f with yields of 20-65 %. 
The yields were low but time didn't permit for optimisation.
Due to the hygroscopic nature and ready decomposition of the silyl derivative 26, it was 
essential that benzylation be conducted immediately. Various techniques were attempted 
to combat the decomposition of compound 26, and its synthesis had to be repeated several 
times; this step should ideally be a one-pot reaction yielding the intermediate 28 to 
minimise decomposition.
Figure 36 illustrates the 13C NMR spectrum of the W-benzylated compound 29d with the 
aromatic carbons resonating downfield at ca. 128 ppm. The benzylic carbon resonates at 
47.15 ppm and the methylene and acetal carbons at ca. 63 ppm and 103 ppm, respectively, 
while the signals corresponding to the methyl groups appear at ca. 16 ppm. Page 70
Figure 36. 400MHz 13C NMR spectrum of compound 29d in CDCU.
Figure 37 illustrates the XH NMR spectrum of compound 29a with the aromatic protons of 
the benzyl group resonating between 7.33 ppm and 7.48 ppm, while the signal 
corresponding to the benzylic protons appears at ca. 4.5 ppm. The phosphonate methylene 
protons resonate as pair of multiplets at ca. 3.6 ppm and the methyl protons below 1.5 
ppm.
Figure 37. 600 MHz XH NMR spectrum of compound 29a in CDCl3.
Page 71
The benzyl substituent introduces a bulky hydrophobic group to take advantage of the third 
binding pocket available in the DXR binding cavity and permits substitution without 
introducing the problem of chirality. The acetal protecting group was removed by acid- 
catalysed hydrolysis to afford each of the aldehydes 30a-f.
The NMR spectra of all compounds confirms the presence of an aldehyde which can be seen 
in the 1H NMR spectrum of compound of 30e (Figure 38) from which the diethyl acetal 
signals are absent and the aldehyde proton signal present at 9.55 ppm. The methylene 
protons adjacent to the aldehyde group resonate at 3.82 ppm, while the signal at 4.25 ppm 
corresponds to the benzylic methylene protons. The phosphonate ethyl ester signals 
resonate, characteristically, at 1.26 ppm and 4.13 ppm. The signals in the aromatic region 
integrate, as expected, for the four aromatic protons.
Figure 39 illustrates the HRMS data for the aldehyde 30f with a pseudo-molecular ion (MH+) 
peak at m/z 354.042 corresponding to the elemental composition C13H19NO4PCl2.
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Figure 39. HRMS data for compound 30f.
The next step involved reductive amination of the aldehydes 30a-f using O- 
benzylhydroxylamine and sodium cyanoborohydride were used to furnish, via an oxime 
intermediate, the O-benzyl-protected amines 31a-f (Scheme 4). Acetylation of compounds 
31a-f was achieved by using acetyl chloride in the presence of triethylamine, to obtain the 
O-benzyl-protected acetyl derivatives 32a-f. The O-benzyl-protection allows for the selective 
acetylation of the second nitrogen which through reduction will yield the hydroxamate 
moiety which is essential for co-ordination to the divalent metal ion.
Figure 40 illustrates the HRMS data of the benzyloxyamino derivativeprotected 32e, with a 
pseudo-molecular ion (MH+) peak at m/z 438.1792 corresponding to the elemental 
composition C20H29N3O6P, while Figure 41 illustrates the 1H NMR spectrum of compound 
32c.
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Scheme 4: Synthesis of W-benzyl-substituted phosphoramidic acid derivatives.
Reagents and conditions: vi) O-benzylhydroxylamine in MeOH, 400C, 3 h and then NaCNBH3, 
MeOH, HCl, r.t., 1 h vii) acetyl chloride, DCM, Et3N, r.t., 24 h, N2 viii) H2, Pd/C, MeOH ix) 
TMSBr, DCM, 00C, 1 h and then H2O, r.t., overnight.
Figure 40. HRMS data for compound 31e.
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Figure 41. 400MHz NMR of compound 32c in CDCU.
The final two steps in the overall synthesis of the target compounds 34 involved removal of 
the O-benzyl protecting group and hydrolysis of the diethyl phosphoramidate ester groups 
(Scheme 5). The O-benzyl protecting group was removed from the intermediates 32 by 
catalytic hydrogenolysis using 10% Pd/C in methanol to yield the corresponding 
hydroxamate derivatives 33. Treatment of these derivatives with TMSBr, followed by 
hydrolysis, yielded the corresponding phosphoramidic acids 34. (It is, of course, possible 
that the diethyl ester intermediates 33a-f could, themselves, serve as ester pro-drugs, 
affording the corresponding phosphoramidic acids 34a-f, through in vivo hydrolysis by 
esterases.) Unfortunately, the yields obtained for the intermediates 32e and 32f were too 
low to continue to compounds 33e and 33f and 34e and 34f, and time did not permit 
repetition of the preceding seven steps to generate more of the intermediate compounds. 
Consequently, the final two steps were completed using compounds 32a-d. Small but 
sufficient quantities of compounds 33a-d and 34a-d were isolated to permit their 
characterization.
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Scheme 5. (Steps viii-ix in overall synthetic sequence)
Reagents and conditions: i) H2, Pd-C, MeOH; ii) TMSBr, DCM; then H2O.
Figure 42 illustrates the 1H NMR spectrum of compound 34d in D2O, while Figure 43 
illustrates the DEPT135 spectrum of compound 34a.
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Figure 42. 1H NMR of compound 34d in D2O.
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Ar-C
Figure 43. DEPT135 NMR of compound 34a in D2 0 .
Compounds 34e and f were not fully characterised at this stage as the yield in the previous 
synthetic step was very low. The yields for compounds 10a-d were also low but some 2-D 
NMR experiments and bioassays could be conducted. Optimisation of the reaction 
conditions for all compounds would lead to higher yields. The molecular modelling data 
revealed that the DXR binding cavity is flexible and, consequently, structurally diverse 
compounds can fit into the binding site. Further analysis of the data will reveal the types of 
ligands that can bind as well as functional groups available in the ligands that can enhance 
attachment to the binding cavity.
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2.3. Enzyme inhibition studies
The target enzyme DXR is involved in the pathway whereby DOXP is converted to MEP 
through intramolecular conversion with co-factor NADPH which performs the subsequent 
reduction.157,158 The bioassays involved the spectroscopic measurement of the conversion of 
NADPH to NADP of enzyme (PfDXR) with known inhibitor compared to where there is one of 
the synthesised ligands bound at the active site of the enzyme. Cytotoxicity studies were 
also conducted for each of the ligands compared to a known inhibitor that has a high 
toxicity towards PfDXR enzyme. Cytotoxicity is a measure of drug-induced cell death, where 
the concentration is gradually increased and the cell viability is measured until at higher 
concentrations cell death usually occurs.188 Cytotoxicity (using Hela cells) and PLDH assays 
were conducted using 20mM solutions in DMSO of the synthesised compounds in 
triplicate.190,191
Cell toxicity A ssa y  IC50
34a
34b
34c
34d
Emetine
Log[uM]
Figure 44. The cytotoxicity IC50 values of known inhibitor, emetine and synthesised ligands 
illustrating percentage viability at increased concentrations of inhibitor.
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The cytotoxicity screening of the ligands; 34a, 34b, 34c and 34d was conducted using 
emetine, a natural alkaloid with an anti-protozoal properties,192 as a standard. The results 
illustrated in Figure 44 reveal that none of the ligands are cytotoxic < 100 compared 
with emetine which exhibits high toxicity at much lower concentrations.
For each of the assays the IC50 value was determined to establish the ligand concentration at 
which 50% inhibition is observed.189 As shown in Figure 45, chloroquine has an IC50 value of 
< 0.1 ^M while the synthesised ligands; 34a, 34b, 34c and 34d have values > 100 ^M.
Figure 45. The IC50 values for inhibition assay of PfDXR enzyme by ligands; 34a, 34b, 34c and 
34d compared to known inhibitor chloroquine, illustrating percentage viability of cell and 
increasing concentrations of ligand.
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2.4. Conclusions
The aims indicated in this research was to evaluate the DXR enzyme active site by 
introducing variation in the structure of fosmidomycin analogues which would allow for the 
determination of the binding site flexibility, affinity as well as structural limitations that the 
site dictates for activity to occur. Our research project consisted of 3 phases; phase 1 was 
the computational study of analogues on DXR enzyme, phase 2 was the synthesis of certain 
analogues that conserved groups essential for activity and finally, phase 3 entailed the use 
of bioassay to observe inhibition exhibited by these analogues.
The in silico studies conducted with both fcDXR and PfDRX on the W-benzyl 
phosphoramidate derivatives reveal high selection for the 2 methylene spacer and methyl 
terminal group, although exceptions occur. This is an observable trend throughout all 
proteins. A series of novel W-benzyl phosphoramidate derivatives were successfully 
synthesised. The W-benzyl derivatives were then used in bioassay against chloroquine and 
showed low inhibition and toxicity. The additional derivatives, the 3-nitro and 3,4-dichloro 
analogue were obtained in low yield and there was not sufficient time to adjust synthetic 
techniques for these compounds.
While it was unfortunate that the analogues' inhibitory activity was significantly lower than 
that of the known inhibitor fosmidomycin and chloroquine, these new compounds provide 
greater insight and depth to our studies in this area.
Future research in this area is being focused on the following:
i) Completion of the synthesis of the 3-nitro- and 3,4-dichlorobenzyl ligands 
(34e and 34f respectively)
ii) Preparation of larger quantities of all the ligands 34a-f for bioassay purposes- 
particularly for PfDXR inhibition assays; and
iii) Optimization of the synthesis and evaluation of a range of furan derivatives 
as conformationally constrained DOXP analogues.
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3. Experimental
3.1. Synthetic Methodology 
General
Synthesis and purification
Starting materials were obtained from Sigma-Aldrich and used without purification. THF and 
benzene distilled from sodium wire and benzophenone under nitrogen. DCM and DMF were 
dried in calcium hydride and distilled under nitrogen. Normal phase thin layer chromato­
graphy plates were used for purification and viewed under UV light (254 nm). Flash 
chromatography was conducted using silica gel 60 (70-230 mesh) for normal phase.
Analysis and Characterisation
NMR spectra was performed on Bruker 400 and 600 MHz spectrometers (T =298 K) and was 
calibrated on the residual protonated solvent signals (for CDCU: 5h = 7.26 ppm; 5c = 77.00 
ppm). High resolution mass spectroscopy was performed on a waters API Q-TOF Ultima 
spectrometer,193 using ionisation mode.
3.1.1. The Synthesis of M-benzyl substituted phosphoramidate derivatives.
Diethyl M-(trimethylsilyl)phosphoramidate 26
A solution of diethyl phosphoramidate (5.0 g, 33 mmol) 25 in benzene (10 ml) was made up 
under Ar gas. Through a septum, hexamethyldisilizane (4.1 ml, 20 mmol) was added while 
stirring. The resulting mixture was heated under reflux in an oil bath at 80 0C for 3 hours. 
The excess solvent was then removed under reduced pressure at 600C for an hour to yield 
diethyl W-(trimethylsilyl) phosphoramidate 26, a brown oil which formed highly hygroscopic 
cream-coloured crystals when cool (4.4524 g, 98% ). 5H/ppm (600 MHz; CDCl3) 0.10 (9H, s, 3 
x CH3SO, 1.20 (6H, t, J = 7.2 Hz, 2 x CH3), 2.79 (1H, s, NH) and 3.85 -  4.00 (4H, m, 2 x O-CH2); 
5c/ppm (600 MHz; CDCU) 0.6 (d, JP-C = 2.4 Hz, 3 x CH3SO, 16.2 (d, JP-C = 7.3 Hz, 2 x CH3) and 
61.9 (d, JP-C = 5.3 Hz, 2 x O-CH2). Page 81
Diethyl M-(2,2-diethoxyethyl) phosphoramidate 28
11
16
15
To a stirred solution of sodium hydride (60 % dispersed in mineral oil; 1.07 g, 26.8 mmol) in 
dry benzene (10 ml) was added through an addition funnel, a solution of diethyl W- 
(trimethylsilyl)phosphoramidate (5.0 g, 22 mmol) 26 in dry benzene (30 ml) slowly over 30 
min under N2 gas. Bromoacetaldehydediethyl acetal (3.3 ml, 22 mmol) and 
tetrabutylammonium bromide (0.71 g, 22 mmol) were then added to the stirred solution 
and the resulting mixture was refluxed at 800C for 4 hours. EtOH (18 ml) was then added 
drop-wise and the mixture was further refluxed for another 1 hour. After cooling, EtOAc 
(100 ml) was added and the organic solution was washed with water (2 x 20 ml). The 
aqueous layers were combined and extracted with EtOAc (3 x 10 ml), the organic layers 
were then combined and dried with anhydr. MgSO4 and the solvent evaporated in vacuo 
300C-400C, yielding diethyl W-(2,2-diethoxyethyl) phosphoramidate 28, a dark brown oil 
(5.6798 g, 92 %). 5H/ppm (600 MHz; CDCU) 1.16 (6H, t, J = 7.2 Hz, 2 x OCH2CH3), 1.25 (6H, t, J 
= 7.2 Hz, 2 x POCH2CH3), 3.94 (1H, s, NH), 3.29 (2H, d, J = 5.2 Hz, CH2N), 3.51 and 3.62 (4H, 
m, 2 x O-CH2), 4.00 (4H, m, 2 x PO-CH2) and 4.59 (1H, t, J = 5.4 Hz, CH); 5c/ppm (600 MHz; 
CDCl3) 15.0 (2 x OCH2CH3)), 15.5 (d, JP-C = 6.5 Hz, 2 x POCH2CH3)), 31.9 (CH2N), 61.8 (d, JP-C 
= 5.8 Hz, 2 x O-CH2), 62.5 (2 x PO-CH2) and 101.1 (C-H).
Diethyl M-benzyl-M- (2,2-diethoxyethyl) phosphoramidate 29a
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To a stirred solution of diethyl W-(2,2-diethoxyethyl) phosphoramidate (1 g, 37 mmol) 28 in 
dry THF (20 ml) under N2 gas, NaH (60 % dispersion in mineral oil; 0.20 g, 74 mmol) was 
added in small portions to permit controlled evolution of hydrogen gas. A solution of benzyl 
bromide (0.44 ml, 3.7 mmol) in dry THF (5 ml) was added and the resulting solution was 
stirred at room temperature (~250C) for ca. 24 hours. The solvent was evaporated in vacuo 
and the residue extracted with EtOAc (2 x 25 ml). The organic layer was sequentially washed 
with saturated aq. NaHCO3 (2 x 50 ml), water (2 x 50 ml) and brine (2 x 50 ml). The aqueous 
washings were then extracted with EtOAc (2 x 25 ml) and the combined organic layers were 
dried using anhydr. MgSO4. The solvent was evaporated in vacuo and the crude product 
chromatographed on silica gel [elution hexane: EtOAc (4:1)] to yield Diethyl W-benzyl-W- 
(2,2-diethoxyethyl) phosphoramidate 29a, a yellow oil (0.735 g, 56.98 %). SH/ppm (600 MHz; 
CDCl3) 1.18 (6H, t, J = 6.8 Hz, 2 x OCH2CH3), 1.27 (6H, t, J = 7.2 Hz, 2 x POCH2CH3), 3.32 (2H, d, 
J = 5.6 Hz, CH2N), 3.51 and 3.64 (4H, m, 2 x O-CH2), 3.85 (2H, s, Ph-CH2), 4.03 (4H, m, 2 x PO- 
CH2), 4.61 (1H, t, J = 5.2 Hz, CH) and 7.29 -  7.37 (5H, m, Ar-H); Sc/ppm (600 MHz; CDCU) 15.1 
(2 x O CH2CH3), 16.1 (d, J p-c = 7.2 Hz, 2 x POCH2CH3), 31.8 (CH2N), 52.7 (3 -CH2), 62.4 (d, Jp-c =
5.5 Hz, 2 x OCH2CH3), 62.7 (2 x POCH2CH3), 101.4 (C-7), 127.3 (C-22), 128.3 (C-20 and C-24), 
128.6 (C-21 and C-23) and 137.4 (C-19).
Diethyl M-(2,2-diethoxyethyl)-M-[4-(hydroxymethyl) benzyl] phosphoramidate 29b
The procedure for the synthesis of Diethyl W-benzyl-W-(2,2-diethoxyethyl) phosphoramidate 
29a was employed using NaH (60 % dispersion in mineral oil; 0.20 g, 7.4 mmol), diethyl W- 
(2,2-diethoxyethyl) phosphoramidate (1.00 g, 3.7 mmol) 28 in dry THF (20 mL) and 4- 
(chloromethyl)benzyl alcohol (0.58 g, 3.7 mmol) in dry THF (5 mL). The solvent was 
evaporated in vacuo and the crude chromatographed on silica gel [elution hexane: EtOAc 
(4:1)] yielding diethyl W-(2,2-diethoxyethyl)-W-[4-(hydroxymethyl)]benzyl) phosphoramidate 
29b, a yellow oil (0.4727 g, 35.01 %). SH/ppm (600 MHz; CDCU) 1.16 (6H, t, J = 7.2 Hz, 2 x 
OCH2CH3), 1.28 (6H, t, J = 6.8 Hz, 2 x POCH2CH3), 2.13 (1H, s, OH), 3.27 (2H, d, J = 5.2 Hz, 
CH2N), 3.48 and 3.61 (4H, m, 2 x OCH2), 3.82 (2H, s, PhCH2), 4.05 (4H, m, 2 x POCH2), 4.47Page 83
(1H, t, J = 5.2 Hz, CH), 4.82 (2H, s, CH2OH) and 7.02 -  7.10 (4H, m, Ar-H); Sc/ppm (600 MHz; 
CDCl3) 15.2 (2 x OCH2CH3), 16.2 (d, J p-c = 7.2 Hz, 2 x POCH2CH3), 33.6 (CH2N), 53.5 (Ph-CH2), 
62.1 (d, J p-c = 6.6 Hz, 2 x O-CH2), 62.5 (2 x PO-CH2), 64.2 (CH2OH), 101.5 (C-7), 127.4 (C-20 
and C-24, 128.7 (C-21 and C-23), 136.1 (C-19) and 139.7 (C-22).
Diethyl M-(3-aminobenzyl)-M-(2,2-diethoxyethyl) phosphoramidate 29c
i) 3-Aminobenzyl bromide 41
Phosphorous tribromide (0.62 ml, 6.5 mmol) was added drop-wise to a stirred solution of 3- 
aminobenzyl alcohol (0.80 g, 6.5 mmol) in dry DCM (10 ml) under N2 at 00C and the resulting 
mixture was stirred for an hour. The mixture was allowed to warm to room temperature 
and stirred for a further 24 hours. After the addition of sat. aq. NaHCO3 (30 ml) and DCM (30 
ml) the organic layer was separated and the aqueous layer was extracted with diethyl ether 
(3 x 20 ml). Organic layers were combined, dried over MgSO4 and filtered. The solvent was 
evaporated in vacuo and crude weighed. A 1:1 solution of KOH was prepared, the crude was 
dissolved in water (10 ml) and the KOH solution added drop-wise at 00 C for an hour. The 
organic layer was extracted with EtOAc (2 x 10 ml) and dried over MgSO4. Yielding 3- 
aminobenzyl bromide 41, a yellow oil (1.5629g, 77%). SH/ppm (400 MHz; DMSO) 4.95 (2H, s, 
NH2), 4.35 (2H, s, CH2Br) and 6.35 - 7.00 (4H, m, Ar- H); Sc/ppm (400 MHz; DMSO) 36.6 
(CH2Br), 115.5 (C-2), 116.4 (C-4), 119.9 (C-6), 129.0 (C-5), 138.0 (C-1) and 147.5 (C-3).
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ii) Diethyl M-(3-aminobenzyl)-M-(2,2-diethoxyethyl)phosphoramidate 29c
14
The procedure for the synthesis of diethyl N-benzyl-N-(2,2-diethoxyethyl)phosphoramidate 
29a was employed using NaH (60 % dispersion in mineral oil; 0.20 g, 7.4 mmol), diethyl N- 
(2,2-diethoxyethyl) phosphoramidate (1.00 g, 3.7 mmol) 28 in dry THF (20 mL) and 3- 
aminobenzyl bromide (0.69 g, 3.7 mmol) in dry THF (5 mL). The solvent was evaporated in 
vacuo and the crude product chromatographed on silica gel [elution hexane: EtOAc (4:1)], 
yielding diethyl N-(3-aminobenzyl)-N-(2,2-diethoxyethyl)phosphoramidate 29c, a yellow oil 
(0.69 g, 49.8%). SH/ppm (600 MHz; CDCU) 1.18 (6H, t, J = 7.2 Hz, OCH2CH3), 1.30 (6H, t, J = 
6.8 Hz, 2 x POCH2CH3), 2.87 (2H, d, J = 5.6 Hz, CH2N), 3.47 and 3.62 (4H, m, 2 x OCH2), 3.83 
(2H, s, Ph-CH2), 3.91 (2H, s, NH2), 4.07 (4H, m, 2 x POCH2), 4.48 (1H, t, J = 5.2 Hz, CH) and 
6.31 -  6.87 (4H, m, Ar-H); Sc/ppm (600 MHz; CDCU) 14.9 (2 x OCH2CH3), 15.9 (d, J p-c = 7.0 Hz, 
2 x POCH2CH3), 31.6 (CH2N), 53.3 (Ph-CH2), 62.1 (d, J p-c = 5.4 Hz, 2 x POCH2), 62.2 (2 x OCH2), 
101.4 (C-7), 127.4 (C-20 and C-24), 128.7 (C-21 and C-23), 136.1 (C-19) and 139.7 (C-22).
Diethyl M-(2,2-diethoxyethyl)-M-(3-mercaptobenzyl)phosphoramidate 29d 
i) 3-Merceptobenzyl bromide 42
A solution of sodium nitrite (0.32 g, 4.6 mmol) in water (2 ml) was slowly added to a mixture 
of 3-aminobenzyl bromide (0.50 g, 2.7 mmol) in water (4 ml) and conc. HCl (1 ml) at -5 -  0 
0C. The mixture was stirred for 1 hour with the temperature kept below 0 0C.
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A solution of sodium sulfide (1.20 g, 4.97 mmol) and sulfur (0.16 g, 5.0 mmol) in water (15 
ml) was then added drop-wise during 1 hour to the cold solution of the diazonium salt and 
the resulting mixture was stirred at 0 0C for 1 hour. After completion, the mixture was 
acidified (pH 2.5) and extracted with EtOAc (3 x 15 ml). The organic extracts were washed 
with 20% Na2CO3 (2 x 20 ml), water (2 x 20ml) and brine (2 x 20ml) and dried with MgSO4 . 
The solvent was removed in vacuo and used in the following step without further 
purification.
In another flask, sodium borohydride (0.12 g, 32 mmol) in THF (3 ml) was added to the 
disulphide solution (0.25 g, 0.8 mmol) in THF (3 ml) under N2 at 0 0C. After the addition, the 
mixture was allowed to warm to room temperature and stirred for an hour. The reaction 
was then quenched with water (6 ml), acidified (pH 2.5) with 2M HCl and extracted with 
EtOAc (3 x 10 ml).
The organic extracts were combined, washed sequentially with 20% Na2CO3 (3 x 10 ml), 
water (3 x 10 ml) and brine (3 x 10 ml) and dried with MgSO4. The solvent was removed in 
vacuo and the residue purified by chromatography on silica [elution with hexane: EtOAc 
(4:1)] to yield 3-mercaptobenzyl bromide 42 as yellow crystals (0.78g, 65%). SH/ppm (400 
MHz; CDCl3) 3.65 (1H, s, SH), 4.65 (2H, s, CH2Br), and 6.60 - 7.46 (4H, m, Ar-H); Sc/ppm (400 
MHz; CDCl3) 36.4 (CH2Br), 125.8 (C-2), 126.4 C-6), 128.3 (C-5), 130.0 (C-4), 130.2 (C-3) and 
137.6 (C-1).
ii) Diethyl M-(2,2-diethoxyethyl)-M-(3-mercaptobenzyl)phosphoramidate 29d
9 O  3
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The procedure for the synthesis of diethyl W-benzyl-W (2,2-diethoxyethyl) phosphoramidate 
29a was employed using NaH (60 % dispersion in mineral oil; 0.20 g, 7.4 mmol), diethyl N- 
(2,2-diethoxyethyl)phosphoramidate (1.00 g, 3.7 mmol) 28 in dry THF (20 mL) and 3- 
sulfanylbenzyl bromide (0.75 g, 3.7 mmol) in dry THF (5 mL). The solvent was evaporated in 
vacuo and the crude chromatographed on silica gel [elution hexane: EtOAc (3:2)] to yield 
diethyl N-(2,2-diethoxyethyl)-N-(3-mercaptobenzyl)phosphoramidate 29d, a yellow oil 
(0.57g, 65%). SH/ppm (600 MHz; CDCU) 1.20 (6H, t, J = 7.2 Hz, 2 x OCH2CH3), 1.29 (6H, t, J = 
6.8 Hz, 2 x POCH2CH3), 2.96 (1H, s, SH), 3.34 (2H, d, J = 5.2 Hz, CH2N), 3.53 and 3.66 (4H, m, 2 
x OCH2), 3.84 (2H, s, Ph-CH2), 4.05 (4H, m, 2 x POCH2), 4.63 (1H, t, J = 5.6 Hz, CH) and 6.89 -  
7.01 (4H, m, Ar-H); Sc/ppm (600 MHz; CDCU) 15.5 (2 x OCH2CH3), 16.5 (d, J p-c = 7.1 Hz, 2 x 
POCH2CH3), 32.2 (CH2N), 49.7 (d, Jp-c = 7.0 Hz, 2 x POCH2), 62.8 (2 x OCH2), 101.0 (CH), 126.8 
(C-7), 124.7 (C-20), 125.5 (C-24), 127.4 (C-22), 129.0 (C-21), 130.0 (C-23), 137.1 (C-19).
Diethyl W-(2,2-diethoxyethyl)-W-(3-nitrobenzyl) phosphoramidate 29e
9 O  3
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The procedure for the synthesis of diethyl W-benzyl-W-(2,2-diethoxyethyl)phosphoramidate 
29a was employed using NaH (60 % dispersion in mineral oil; 0.20 g, 7.4 mmol), diethyl W- 
(2,2-diethoxyethyl) phosphoramidate (1.00 g, 3.7 mmol) 28 in dry THF (20 mL) and 3- 
nitrobenzyl bromide (0.814 g, 3.7 mmol) in dry THF (5 mL). The solvent was evaporated in 
vacuo and the crude chromatographed on silica gel [elution hexane: EtOAc (4:1)] to yield 
diethyl W-(2,2-diethoxyethyl)-W-(3-nitrobenzyl)phosphoramidate 29e, a dark green oil (0.302 
g, 20.2%). SH/ppm (600 MHz; CDCU) 1.11 (6H, t, J = 6.8 Hz, 2 x OCH2CH3), 1.12 (6H, t, J = 7.2 
Hz, 2 x P OCH2CH3), 2.85 (2H, d, J = 5.6 Hz, CH2N), 3.41 (4H, m, 2 x OCH2), 3.81 (2H, s, Ph-Page 87
CH2), 4.07 (4H, m, 2 x POCH2), 4.43 (1H, t, J = 5.2 Hz, CH) and 7.32 -  8.07 (4H, m, Ar-H); 
Sc/ppm (600 MHz; CDCfe) 15.5 (2 x OCH2CH3), 14.5 (d, J p-c = 7.2 Hz, 2 x POCH2CH3), 44.5 
(CH2N), 69.5 (Ph-CH2), 61.4 (d, Jp-c = 5.5 Hz, 2 x POCH2), 60.7 (2 x OCH2), 100.2 (CH), 120.4 (C- 
7), 124.8 (C-20), 126.7 (C-21), 128.0 (C-22), 129.1 (C-24), 130.0 (C-19), 137.7 (C-23).
Diethyl N-(3,4 dichlorobenzyl)-N-(2,2-diethoxyethyl)phosphoramidate 29f
2
9 O  3
The procedure for the synthesis of diethyl W-benzyl-W- (2,2-diethoxyethyl) phosphoramidate 
29a was employed using NaH (60 % dispersion in mineral oil; 0.20 g, 7.4 mmol), diethyl W- 
(2,2-diethoxyethyl)phosphoramidate (1.00 g, 3.7 mmol) 28 in dry THF (20 mL) and 3, 4 
dichlorobenzyl chloride (0.51 ml, 37 mmol) in dry THF (5 ml). The solvent was evaporated in 
vacuo and the crude chromatographed on silica gel [elution hexane: EtOAc (4:1)] to yield 
diethyl W-(3,4 dichlorobenzyl)-W-(2,2-diethoxyethyl)phosphoramidate 29f, a yellow oil 
(0.488g, 30.7%). SH/ppm (600 MHz; CDCU) 1.25 (6H, t, J = 6.8 Hz, 2 x OCH2CH3), 1.31 (6H, t, J 
= 7.2 Hz, 2 x POCH2CH3), 3.31 (2H, d, J = 5.6 Hz, CH2N), 3.61 (4H, m, 2 x OCH2), 4.01 (2H, s, 
Ph-CH2), 4.17 (4H, m, 2 x POCH2), 4.58 (1H, t, J = 5.2 Hz, CH) and 7.02 -  7.55 (3H, m, Ar-H); 
Sc/ppm (600 MHz; CDCU) 15.5 (2 x OCH2CH3), 14.5 (d, Jp-c = 7.2 Hz, 2 x POCH2CH3), 44.6 
(CH2N), 69.0 (Ph-CH2), 61.4 (d, J p-c = 5.5 Hz, 2 x POCH2), 60.1 (2 x OCH2), 100.2 (CH), 127.0 (C- 
7), (C-19), (C-20), (C-21), (C24), (C-22), 136.4 (C-23).
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Diethyl W-benzyl-W-(2-oxoethyl)phosphoramidate 30a
2
9 O  3
H
Diethyl W-benzyl-W-(2,2diethoxyethyl) phosphoramidate (0.5 g, 1.4 mmol) 29a and 2M HCl 
(4 ml) were stirred at room temperature for approximately 24 hours. After completion the 
reaction mixture was added to CHCl3 (20 ml) and the organic phase was washed with water 
(3 x 20 ml). The aqueous washings were combined and extracted with CHCU (30 ml). The 
combined organic extracts were sequentially washed with saturated aq. NaHCO3 (3 x 20 ml) 
and brine (3 x 20 ml) and then dried with anhydr. MgSO4 . The solvent was evaporated in 
vacuo and the residue chromatographed on silica gel (4:1) to yield diethyl W-benzyl-W-(2- 
oxoethyl)phosphoramidate 30a, a yellow oil (0.35g, 70%). SH/ppm (600 MHz; CDCl3) 1.33 
(6H, t, J = 6.8 Hz, 2 x POCH2CH3), 3.74 (2H, d, J = 6.0 Hz, CH2CO), 3.83 (2H, s, Ph-CH2), 4.12 
(4H, m, 2 x OCH2), 7.31 -  7.37 (5H, m, Ar-H) and 9.82 (1H, s, CHO); Sc/ppm (600 MHz; CDCb)
16.2 (d, J p-c = 5.9 Hz, 2 x POCH2CH3), 51.9 (d, Jp-c = 6.0 Hz, CH2CO), 62.4 (d, J p-c = 6.5 Hz, 2 x 
OCH2), 67.6 (Ph-CH2), 127.6 (C-18), 128.0 (C-16 and C-20), 128.1 (C-17 and C-19), 137.7 (C- 
15) and 175.2 (C=O).
Diethyl W-[4-(hydroxymethyl)benzyl]-W-(2-oxoethyl)phosphoramidate 30b
21
2
1
OH
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The procedure described for the synthesis of diethyl N-benzyl-N-(2-oxoethyl)- 
phosphoramidate 30a was employed using diethyl N-(2,2-diethoxyethyl)-N-[4- 
(hydroxymethyl)benzyl]phosphoramidate (0.5 g, 1.3 mmol) 29b and 2M HCl (4 ml). After 
work up, the solvent was removed in vacuo and the residue chromatographed on silica gel 
(4:1) to yield diethyl N-[4-(hydroxymethyl)benzyl]-N-(2-oxoethyl)phosphoramidate 30b, a 
yellow oil (0.36g, 72%). SH/ppm (600 MHz; CDCU) 1.36 (6H, t, J = 7.2 Hz, 2 x CH3), 2.03 (1H, s, 
OH), 3.72 (2H, d, J = 5.2 Hz, CH2CO), 3.82 (2H, s, PhO-h), 4.18 (4H, m, 2 x OCH2), 4.82 (2H, s, 
CH2OH), 7.09 -  7.17 (4H, m, Ar-H) and 9.81 (1H, s, CHO); Sc/ppm (600 MHz; CDCU) 16.3 (d, 
JP-C = 5.8 Hz, 2 x CH3), 48.9 (d, J p-c = 5.9 Hz, CH2CO), 63.0 (d, J p-c = 6.3 Hz, 2 x OCH2), 64.9 
(CH2OH), 67.2 (Ph-CH2), 127.1 (C-20 and C-16), 128.2 (C-17 and C-19), 135.8 (C-15), 139.8 (C- 
18) and 172.8 (C=O).
Diethyl W-(3-aminobenzyl)-W-(2-oxoethyl) phosphoramidate 30c
9 O  3
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The procedure described for the synthesis of diethyl N-benzyl-N-(2-oxoethyl)- 
phosphoramidate 30a was employed using diethyl N-(3-aminobenzyl)-N-(2,2diethoxyethyl)- 
phosphoramidate (0.5 g, 1.3 mmol) 29c and 2M HCl (4 ml). After work up, the solvent was 
removed in vacuo and the residue chromatographed on silica gel (4:1) to yield diethyl N-(3- 
aminobenzyl)-N-(2-oxoethyl)phosphoramidate 30c, a yellow oil (0.37g, 74%). SH/ppm (600 
MHz; CDCl3) 1.35 (6H, t, J = 6.8 Hz, 2 x CH3), 3.24 (2H, s, NH2), 3.71 (2H, d, J = 5.2 Hz, CH2CO), 
3.83 (2H, s, Ph-CH2), 4.17 (4H, m, 2 x OCH2), 7.00 -  7.47 (4H, m, Ar-H) and 9.81 (1H, s, CHO); 
So/ppm (600 MHz; CDCU) 16.3 (d, J p-c = 6.0 Hz, 2 x CH3), 52.8 (d, J p-c = 4.9 Hz, CH2CO), 61.7
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(d, J p-c = 6.4 Hz, 2 x OCH2), 68.3 (Ph-CH2), 114.0 (C-18), 114.9 (C-20), 118.3 (C- 18), 129.8 (C- 
17), 137.7 (C-15), 147.8 (C-19) and 174.8 (C=O).
Diethyl M-(3-mercaptobenzyl)-M-(2-oxoethyl)phosphoramidate 30d
1
SH
The procedure described for the synthesis of diethyl N-benzyl-N-(2-oxoethyl)- 
phosphoramidate 30a was employed using diethyl N-(3-mercaptobenzyl)-N-
(2,2diethoxyethyl)phosphoramidate (0.5 g, 1.3 mmol) 29d and 2M HCl (4 ml). After work up, 
the solvent was removed in vacuo and the residue chromatographed on silica gel (4:1) to 
yield diethyl N-(3-mercaptobenzyl)-N-(2-oxoethyl)phosphoramidate 30d, a yellow oil (0.37g, 
74%). SH/ppm (600 MHz; CDCU) 1.36 (6H, t, J = 7.2 Hz, 2 x CH3), 2.77 (1H, s, SH), 3.53 (2H, d, J 
= 6.0 Hz, CH2CO), 3.79 (2H, s, Ph-O-h), 4.12 (4H, m, 2 x O-CH2), 6.86 -  7.40 (4H, m, Ar-H) and 
9.87 (1H, s, CHO); So/ppm (600 MHz; CDCfe) 16.4 (d, J p-c = 6.0 Hz, 2 x CH3), 52.7 (d, J p-c = 4.7 
Hz, CH2CO), 61.4 (d, J p-c = 6.4 Hz, 2 x OCH2), 68.6 (Ph-CH2), 124.6 (C-16), 126.2 (C-20), 127.8 
(C-18), 128.3 (C-17), 130.4 (C-19), 137.7 (C-15) and 173.2 (C=O).
Diethyl W-(3-nitrobenzyl)-W-(2-oxoethyl) phosphoramidate 30e
9
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The procedure described for the synthesis of diethyl N-benzyl-N-(2-oxoethyl)- 
phosphoramidate 30a was employed using Diethyl N-(3-nitrobenzyl)-N-(2,2-diethoxyethyl)- 
phosphoramidate (0.3 g, 0.91 mmol) 29e and 2M HCl (2.5 ml). After work up, the solvent 
was removed in vacuo and the residue chromatographed on silica gel (4:1) to yield diethyl 
N-(3-nitrobenzyl)-N-(2-oxoethyl) phosphoramidate 30e, a green oil (0.25g, 83%). SH/ppm 
(600 MHz; CDCfe) 1.11 (6H, t, J = 6.8 Hz, 2 x CH3),3.65 (2H, d, J = 6.0 Hz, CH2CO), 3.81 (2H, s, 
Ph-CH2),4.07 (4H, m, 2 x OCH2), 7.30-8.07 (4H, m, Ar-H) and 9.72 (1H, s, CHO); So/ppm (600 
MHz; CDCl3) 14.4 (d, J p-c = 5.9 Hz, 2 x CH3), 52.0 (d, J p-c = 6.0 Hz, CH2CO), 60.02(d, J p-c = 6.5 
Hz, 2 x OCH2), 68.5 (Ph-CH2), 142.6-146.5 (Ar-C), 200.0 (C=O).
Diethyl N-(3,4 dichlorobenzyl)-N-(2-oxoethyl)phosphoramidate 30f
The procedure described for the synthesis of diethyl N-benzyl-N-(2-oxoethyl)- 
phosphoramidate 30a was employed using diethyl N-(3,4-dichlorobenzyl)-N-
(2,2diethoxyethyl)phosphoramidate (0.4 g, 1.13 mmol) 29f and 2M HCl (3.2 ml). After work 
up, the solvent was removed in vacuo and the residue chromatographed on silica gel (4:1) to 
yield diethyl N-(3,4 dichlorobenzyl)-N-(2-oxoethyl) phosphoramidate 30f, a yellow oil (0.30g, 
75%). SH/ppm (600 MHz; CDCfe) 1.11 (6H, t, J = 6.8 Hz, 2 x CH3), 3.55 (2H, d, J = 6.0 Hz, 
CH2CO), 3.82 (2H, s, Ph-CH2), 4.07 (4H, m, 2 x O-CH2), 6.80-7.09 (3H, m, Ar-H) and 9.72 (1H, 
s, CHO); So/ppm (600 MHz; CDCfe) 14.4 (d, J p-c = 5.9 Hz, 2 x CH3), 52.1 (d, J p-c = 6.0 Hz, 
CH2CO), 60.0 (d, J p-c = 6.5 Hz, 2 x O-CH2), 68.3 (Ph-O-h), 127.6-133.2 (Ar-C), 199.5 (C=O).
Page 92
Diethyl N-benzyl-N-[2-(benzyloxyamino)ethyl]phosphoramidate 31a
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To a stirred solution of diethyl N-benzyl-N-(2-oxoethyl)phosphoramidate (0.30 g, 1.05 mmol) 
30a in MeOH (5 mL) was added a solution of O-benzylhydroxylamine (0.15 g, 1.29 mmol) in 
MeOH (8 mL). The reaction mixture was heated at 400C for 3 hours, cooled to room 
temperature and diluted with MeOH (50 mL). After the addition of sodium 
cyanoborohydride (0.20 g, 3.1 mmol), conc. HCl (1.2 mL) was added dropwise over a period 
of 30 min and the mixture was stirred for 1 hour. Sodium cyanoborohydride (0.075 g, 1.05 
mmol) was again added and the mixture was stirred for 1 hour. The solvent was removed 
under reduced pressure, the residue dissolved in MeOH (30 mL) and then treated with ice- 
water (50 mL). The pH of the resulting mixture was adjusted to pH 10 with an aq. KOH 
solution and extracted with DCM (3 x 20 mL). The combined organic layers were washed 
with 10 % NaHCO3 (50 mL) and brine (50 mL) and then dried (anhydr. MgSO4). The solvent 
was evaporated in vacuo and the residual oil was purified by flash chromatography on silica 
gel [elution with hexane-EtOAc (3:1)] to yield diethyl N-benzyl-N-[2-(benzyloxyamino)ethyl]- 
phosphoramidate 31a, a yellow oil (0.20 g 50 %). SH/ppm (600 MHz; CDCU) 1.32 (6H, t, J =
7.2 Hz, 2 x CH3), 2.89 (4H, m, NCH2), 3.82 (2H, s, Ph-CH2), 4.10 (4H, m, 2 x OCH2), 4.74 (2H, s, 
OCH2Ph), 5.23 (1H, s, NH) and 7.29 -  7.37 (10H, m, Ar-H); So/ppm (600 MHz; CDCU) 16.5 (d, 
J p-c = 6.0 Hz, 2 x CH3), 36.7 (d, J p-c = 4.5 Hz, NCH2), 52.1 (d, J p-c = 16.7 Hz, NCH2), 61.5 (d, J p-c 
= 6.4 Hz, 2 x POCH2), 67.3 (Ph-O-h), 68.3 (OO-hPh), 113.9 (C-17), 114.9 (C-19), 118.3 (C15), 
126.9 (C-23 and C-27), 127.8 (C-25), 128.3 (C-24 and C-26), 129.3 (C-16), 136.7 (C-14), 137.7 
(C-22) and 148.3 (C-18).
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Diethyl M-[2-(benzyloxyamino)ethyl]-M-(hydroxymethyl)benzyl]phosphoramidate 31b
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The procedure described for the synthesis of diethyl N-benzyl-N-[2-(benzyloxyamino)ethyl]- 
phosphoramidate 31a was employed, using diethyl N-[4-(hydroxymethyl)benzyl]-N- 
(2oxoethyl phosphoramidate (0.32 g, 1.0 mmol) 30b, O-benzylhydroxylamine (0.16 g, 1.28 
mmol) in MeOH (10 mL), sodium cyanoborohydride (0.18 g, 2.90 mmol), conc. HCl (1.2 mL) 
and a further portion of sodium cyanoborohydride (0.061 g, 0.92 mmol). After work-up, the 
solvent was evaporated in vacuo and the remaining oil was purified by flash 
chromatography on silica gel [elution with hexane-EtOAc (3:1)] to yield diethyl N-[2- 
(benzyloxyamino)ethyl]-N-[4(hydroxymethyl)benzyl]phosphoramidate 31b, a yellow oil 
(0.22 g, 53 %). SH/ppm (600 MHz; CDCls) 1.29 (6H, t, J = 7.2 Hz, 2 x CHs), 2.87 (4H, m, NCH2), 
3.80 (2H, s, Ph-CH2), 4.07 (4H, m, 2 x POCH2), 4.77 (2H, s, OCH2Ph ), 4.86 (2H, s, CH2OH), 7.33 
-  7.42 (9H, m, Ar-H), 7.97 (1H, s, OH) and 8.11 (1H, s, NH); Sc/ppm (600 MHz; CDCl3) 16.3 (d, 
J p-c = 6.0 Hz, 2 x CH3), 36.4 (d, Jp-c = 4.8 Hz, N-CH2), 52.0 (d, Jp-c = 16.4 Hz, N-CH2), 61.3 (d, Jp-c 
= 6.5 Hz, 2 x POCH2), 64.7 (CH2OH), 67.2 (OCH2Ph), 69.2 (Ph-CH2), 127.7 (C-19 and C-15), 
127.8 (c-23 and c-27), 128.2 (c-25), 128.3 (c-18 and c-16), 128.3 (c-24 and c-26), 137.4 (c- 
14), 137.8 (C-22) and 138.3 (C-17).
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Diethyl W-(3-ammobenzyl)-W-[2-(benzyloxyammo)ethyl]phosphoramidate 31c
1
2<9 O  3
N H 228
21 27 26
2524
The procedure described for the synthesis of diethyl N-benzyl-N-[2-
(benzyloxyamino)ethyl]=phosphoramidate 31a was employed, using diethyl N-(3- 
aminobenzyl)-N-(2oxoethyl)phosphoramidate (0.34 g, 1.16 mmol) 30c, O-benzyl-
hydroxylamine (0.17 g, 1.39 mmol) in MeOH (10 mL), sodium cyanoborohydride (0.22 g, 
3.46 mmol), conc. HCl (1.2 mL) and a further portion of sodium cyanoborohydride (0.070 g, 
1.01 mmol). After work-up, the solvent was evaporated in vacuo and the remaining oil was 
purified by flash chromatography on silica gel [elution with hexane-EtOAc (3:1)] to yield 
diethyl N-(3-aminobenzyl)-N-[2(benzyloxyamino)ethyl]phosphoramidate 31c, a yellow oil 
(0.25 g, 57 %). SH/ppm (600 MHz; CDCU) 1.22 (6H, t, J = 6.0 Hz, 2 x CH3), 2.95 (4H, m, N-CH2), 
3.59 (2H, s, OCH2Ph), 4.03 (4H, m, 2 x POCH2), 4.62 (2H, s, Ph-CH2), 5.55 (2H, s, NH2), 6.59 -
6.87 (4H, m, Ar-H), 7.28-7.37 (5H, m, Ar-H) and 8.40 (1H, s, NH); So/ppm (600 MHz; CDCU)
16.4 (d, JP-C = 6.0 Hz, 2 x CH3), 36.5 (d, J p-c = 4.8 Hz, N-CH2), 52.0 (d, J p-c = 16.7 Hz, N-CH2),
61.5 (d, Jp-c = 6.5 Hz, 2 x POCH2), 67.4 (Ph-Q-h), 69.9 (OCH2Ph), 113.9 (C-17), 114.9 (C-19),
118.3 (C-15), 126.9 (C-23 and C-27), 127.8 (C-25), 128.3 (C-24 and C-26), 129.3 (C-16), 136.7 
(C-14), 137.7 (C-22) and 148.3 (C-18).
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Diethyl M-[2-(benzyloxyamino)ethyl]-M-(3-mercaptobenzyl)phosphoramidate 31d
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The procedure described for the synthesis of diethyl N-benzyl-N-[2-(benzyloxyamino)ethyl]- 
phosphoramidate 31a was employed, using diethyl N-(3-mercaptobenzyl)-N-(2oxoethyl) 
phosphoramidate (0.34 g, 1.08 mmol) 30d, O-benzylhydroxylamine (0.108 g, 0.85 mmol) in 
MeOH (10 mL), sodium cyanoborohydride (0.21 g, 3.3 mmol), conc. HCl (1.2 mL) and a 
further portion of sodium cyanoborohydride (0.070 g, 1.005 mmol). After work-up, the 
solvent was evaporated in vacuo and the remaining oil was purified by flash 
chromatography on silica gel [elution with hexane-EtOAc (3:1)] to yield diethyl N-[2- 
(benzyloxyamino)ethyl]-N-(3-mercaptobenzyl)phosphoramidate 31d, a yellow oil (0.24 g, 55 
%). SH/ppm (600 MHz; CDCU) 1.28 (6H, t, J = 7.2 Hz, 2 x CH3), 2.61 (4H, m, N-CH2), 3.38 (1H, 
s, SH), 3.61 (2H, s, Ph-CH2), 4.04 (4H, m, 2 x POCH2), 4.81 (2H, s, OCH2Ph), 6.75 - 7.18 (4H, m, 
Ar-H), 7.31 - 7.35 (5H, m, Ar-H) and 8.18 (1H, s, NH); Sc/ppm (600 MHz; CDCU) 16.4 (d, Jp-c = 
6.0 Hz, 2 x CH3), 36.8 (d, Jp-c = 4.8 Hz, N-CH2), 52.1 (d, Jp-c = 16.7 Hz, N-CH2), 61.5 (d, J p-c = 6.5 
Hz, 2 x POcH2), 66.7 (OcH2Ph), 71.2 (Ph-O-h), 124.6 (c-15), 125.9 (c-19), 127.6 (c-17), 127.9 
(c-23 and c-27), 128.0 (c-25), 128.3 (c-16), 128.4 (c-24 and c-26), 130.6 (c-18) and 137.8 (c- 
14) and 138.0 (c-22).
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Diethyl M-[2-(benzyloxyamino)ethyl]-M-(3-nitrobenzyl)phosphoramidate 31e
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The procedure described for the synthesis of diethyl N-benzyl-N-[2-(benzyloxyamino)ethyl]- 
phosphoramidate 31a was employed, using diethyl N-(3-nitrobenzyl)-N-(2-oxoethyl) 
phosphoramidate (0.25 g, 0.57 mmol) 30e, O-benzylhydroxylamine in MeOH (10 mL), 
sodium cyanoborohydride, conc. Hcl (mL) and a further portion of sodium 
cyanoborohydride. After work-up, the solvent was evaporated in vacuo and the remaining 
oil was purified by flash chromatography [on silica gel; elution with hexane-EtOAc (3:1)] to 
yield diethyl N-[2-(benzyloxyamino)ethyl]-N-(3-nitrobenzyl)phosphoramidate, a light green 
oil (0.14 g, 56 %) 31e. SH/ppm (600 MHz; cDcU) 1.11 (6H, t, J = 7.2 Hz, 2 x cH3), 2.03 (1H, s, 
NH), 2.77-2.81 (4H, m, N-Q-h), 3.82 (2H, s, Ph-cH2), 4.10 (4H, m, 2 x POQ-h), 4.74 (2H, s, 
OcH2Ph) and 7.91 -  8.01 (10H, m, Ar-H); Sc/ppm (600 MHz; cDcU) 14.5 (d, J p-c = 6.0 Hz, 2 x 
cH3), 37.7 (d, J p-c = 4.5 Hz, N-cH2), 51.2 (d, Jp-c = 16.7 Hz, N-G-h), 60.0 (d, Jp-c = 6.4 Hz, 2 x 
POcH2), 68.9 (Ph-cH2), 77.3 (OcH2Ph), 120.9-156.4 (11 x Ar-c).
Diethyl M-[2-(benzyloxyamino)ethyl-M-(3,4-dichlorobenzyl)phosphoramidate 31f
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The procedure described for the synthesis of diethyl N-benzyl-N-[2-(benzyloxyamino)ethyl]- 
phosphoramidate 31a was employed, using diethyl N-(3,4-dichlorobenzyl)-N-(2oxoethyl)- 
phosphoramidate (0.30 g, 0.65 mmol) 30f, O-benzylhydroxylamine in MeOH (10 mL), 
sodium cyanoborohydride, conc. Hcl (1.2 mL) and a further portion of sodium 
cyanoborohydride. After work-up, the solvent was evaporated in vacuo and the remaining 
oil was purified by flash chromatography [on silica gel; elution with hexane-EtOAc (3:1)] to 
yield diethyl N-[2-(benzyloxyamino)ethyl]-N-(3,4-dichlorobenzyl)phosphoramidate, a yellow 
oil (0.20 g, 67 %) 31f. SH/ppm (600 MHz; cDcU) 1.12 (6H, t, J = 7.2 Hz, 2 x a-b), 2.0 (1H, s, 
NH), 2.77-2.81 (4H, m, N-cH2), 3.81 (2H, s, Ph-cH2), 4.07 (4H, m, 2 x POc-h), 4.79 (2H, s, 
OcH2Ph) and 6.88 -  7.19 (8H, m, Ar-H); Sc/ppm (600 MHz; cDcl3) 14.5 (d, J p-c = 6.0 Hz, 2 x 
cH3), 37.7 (d, J p-c = 4.5 Hz, N-cH2), 51.2 (d, Jp-c = 16.7 Hz, N-cH2), 60.0 (d, Jp-c = 6.4 Hz, 2 x 
POcH2), 68.4 (Ph-cH2), 77.0 (OcH2Ph), 127.2-141.4 (11 x Ar-c).
Diethyl M-benzyl-2-[M-(benzyloxy)acetamido]ethylphosphoramidate 32a
26
25
Acetyl chloride (0.12 mL, 1.3 mmol) was added dropwise to a stirred solution of diethyl N 
benzyl-N-[2-(benzyloxyamino)ethyl]phosphoramidate (0.25 g, 0.64 mmol) 31a and 
triethylamine (0.13 mL, 0.96 mmol) in DcM (10 mL) under N2 at 0 oc. The mixture was 
stirred at 0 0c for 1 hour, allowed to warm to room temperature and then stirred for ca. 24 
hours. The solvent was removed under reduced pressure and the residual oil dissolved in 
diethyl ether (20 mL). The ethereal solution was washed sequentially with aq. K2cO3 
solution, 0.5M-Hcl and water. The organic solution was dried over anhydr. MgSO4, the 
solvent removed in vacuo and the residue purified by flash chromatography [on silica gel;
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elution with hexane-EtOAc (7:3)] to yield diethyl N-benzyl-2-[N-benzyloxy)acetamido]ethyl- 
phosphoramidate 32a, a yellow oil (0.17 g, 80 %). SH/ppm (600 MHz; cDcl3) 1.29 (6H, t, J =
7.2 Hz, 2 x cH3), 2.00 (3H, s, cH3cO), 2.71 (2H, m, N-cH2), 3.01 (2H, t, J = 6.4 Hz, N-cH2), 3.67 
(2H, s, Ph-cH2), 4.08 (4H, m, 2 x POcH2), 4.77 (2H, s, OcH2Ph) and 7.27 - 7.39 (9H, m, Ar-H); 
Sc/ppm (600 MHz; cDcU) 16.4 (d, J p-c = 5.9 Hz, 2 x PO-cH3), 23.7 (cH3cO), 35.4 (d, J p-c = 5.4 
Hz, NcH2), 52.6 (d, J p-c = 16.8 Hz, NcH2), 62.5 (d, J p-c = 6.7 Hz, 2 x POc-h), 66.8 (Ph-cH2), 68.7 
(OcH2ph), 124.8 (c-17), 124.9 (c-25), 127.5 (c-19 and c-15), 127.8 (c-23 and c-27), 128.5 (c- 
18 and c-16), 128.7 (c-24 and c-26), 138.3 (c-14), 138.4 (c-22) and 171.6 (c=O).
Diethyl-2-[W-(benzyloxy)acetamido]-W-[4(hydroxymethyl)benzyl]ethylphosphoramidate
32b
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The procedure described for the synthesis of diethyl N-benzyl-2-[N-
benzyloxy)acetamido]ethylphosphoramidate 32a was employed, using diethyl N-[2- 
(benzyloxyamino)ethyl]-N-[4(hydroxymethyl)benzyl]phosphoramidate 31b (0.25 g, 0.59 
mmol), acetyl chloride (0.12 mL, 1.3 mmol) and triethylamine (0.12 mL, 0.89 mmol) in DcM 
(10 mL). The solvent was evaporated in vacuo and the residue was purified by flash 
chromatography on silica gel; elution with hexane-EtOAc (7:3) to yield diethyl 2-[(N- 
benzyloxy)acetamido]-N-[4(hydroxymethyl)benzyl]ethyl phosphoramidate, a yellow oil (0.12 
g, 60 %) 32b. SH/ppm (600 MHz; cDcU) 1.32 (6H, t, J = 7.2 Hz, 2 x cH3), 2.04 (3H, s, cH3cO), 
2.32 (2H, m, N-cH2), 2.76 (2H, t, J = 6.0 Hz, N-cH2), 3.71 (2H, s, Ph-c-h), 4.11 (4H, m, 2 x PO- 
cH2), 4.79 (2H, s, Ph-cH2), 4.84 (2H, s, cH2OH), 7.22 - 7.43 (9H, m, Ar-H) and 8.22 (1H, s, OH); 
Sc/ppm (600 MHz; cDcfe) 16.4 (d, Jp-c = 5.9 Hz, 2 x cH3), 23.0 (c^cO ), 36.8 (d, Jp-c = 4.1 Hz, 
N-cH2), 52.8 (d, Jp-c = 16.6 Hz, N-cH2), 62.3 (d, Jp-c = 6.6 Hz, 2 x POcH2), 65.9 (cH2OH), 66.6
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(Ph-cH2), 68.7 (OcH2Ph), 126.3 (c-19 and c-15), 126.4 (c-23 and c-27), 126.8 (c-25), 127.0 
(c-18 and c-16), 127.7 (c-24 and c-26), 137.2 (c-14), 137.4 (c-22), 140.2 (c-17) and 171.1 
(c=O).
Diethyl M-(3-aminobenzyl)-2-[(M-benzyloxy)acetamido]ethylphosphoramidate 32c
i
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The procedure described for the synthesis of diethyl N-benzyl-2-[N-
benzyloxy)acetamido]ethylphosphoramidate 32a was employed, using diethyl N-[2- 
(benzyloxyamino)ethyl]-N-(3mercaptobenzyl)phosphoramidate 31c (0.28 g, 0.68 mmol), 
acetyl chloride (0.13 mL, 1.4 mmol) and triethylamine (0.14 mL, 1.0 mmol) in DcM (10 mL). 
The solvent was evaporated in vacuo and the residue was purified by flash chromatography 
[on silica gel; elution with hexane-EtOAc (7:3)] to yield diethyl N-(3-aminobenzyl)-2-[(N- 
benzyloxy)acetamido]ethylphosphoramidate, a yellow oil 32c (0.11 g, 55 %). SH/ppm (600 
MHz; cDcl3) 1.30 (6H, t, J = 7.2 Hz, 2 x cH3), 2.02 (3H, s, cH3cO), 2.81 (2H, m, N-c-h), 3.23 
(2H, t, J = 4.4 Hz, N-cH2), 3.79 (2H, s, Ph-cH2), 4.08 (4H, m, 2 x POcH2), 4.52 (2H, s, NH2), 4.81 
(2H, s, Ph-cH2), 6.63 - 6.78 (4H, m, Ar-H) and 7.16 - 7.19 (5H, m Ar-H); Sc/ppm (600 MHz; 
cDcl3) 16.4 (d, Jp-c = 6.6 Hz, 2 x c-U), 23.8 (c^cO ), 36.7 (d, Jp-c = 4.7 Hz, NcH2), 52.1 (d, Jp-c = 
16.7 Hz, N-cH2), 61.4 (d, J p-c = 6.5 Hz, 2 x POcH2), 68.4 (Ph-c-h), 69.8 (OcH2Ph), 114.1 (c-17), 
114.8 (c-19), 118.6 (c-15), 126.5 (c-23 and c-27), 127.8 (c-25), 128.3 (c-24 and c-26), 129.8 
(c-16), 137.3 (c-14), 137.7 (c-22), 147.9 (c-18) and 170.8 (c=O).
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Diethyl 2-[(M-benzyloxy)acetamido]-M-(3-mercaptobenzyl)ethylphosphoramidate 32d
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The procedure described for the synthesis of diethyl N-benzyl-2-[N-
benzyloxy)acetamido]ethylphosphoramidate 32a was employed, using diethyl N-[2- 
(benzyloxyamino)ethyl]-N-(3mercaptobenzyl)phosphoramidate 31d (0.27 g, 0.64 mmol), 
acetyl chloride (0.12 mL, 1.3 mmol) and triethylamine (0.12 mL, 0.88 mmol) in DcM (10 mL). 
The solvent was evaporated in vacuo and the residue was purified by flash chromatography 
[on silica gel; elution with hexane-EtOAc (7:3)] to yield diethyl 2-[(N-benzyloxy)acetamido]- 
N-(3-mercaptobenzyl)ethylphosphoramidate 32d, a yellow oil (0.1 g, 50 %). S-/ppm (600 
MHz; cDcl3) 1.36 (6H, t, J = 7.2 Hz, 2 x cH3), 2.20 (3H, s, cH3cO), 2.79 (2H, m, N-cH2), 3.25 
(2H, t, J = 5.6 Hz, N-cH2), 3.83 (2H, s, Ph-c-h), 4.19 (4H, m, 2 x PO-c-h), 4.71 (2H, s, Ph-c-h), 
6.21 (1H, s, SH), 6.63 - 7.29 (4H, m, Ar-H) and 7.42 - 7.50 (5H, m, Ar-H); Sc/ppm (600 MHz; 
cDcl3) 16.4 (d, Jp-c = 5.9 Hz, 2 x c-^), 24.2 (c^cO ), 36.7 (d, Jp-c = 4.8 Hz, Nc-h), 52.9 (d, Jp-c 
= 16.8 Hz, N-cH2), 61.6 (d, J p-c = 6.5 Hz, 2 x POc-h), 68.1 (Ph-cH2), 70.8 (OcH2Ph), 124.7 (c- 
15), 126.0 (c-19), 126.2 (c-17), 126.8 (c-23 and c-27), 128.7 (c-25), 129.1 (c-16), 129.4 (c-24 
and c-26), 130.3 (c-18), 138.5 (c-14), 138.8 (c-16) and 167.3 (c=O).
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Diethyl M-benzyl-2-[M-(3-nitrobenzyl)acetamido]ethylphosphoramidate 32e
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The procedure described for the synthesis of diethyl N-benzyl-2-[N-
benzyloxy)acetamido]ethylphosphoramidate 32a was employed, using diethyl N-[2- 
(benzyloxyamino)ethyl]-N-(3-nitrobenzyl)phosphoramidate (0.27 g, 0.64 mmol) 31e, acetyl 
chloride (0.12 mL, 1.3 mmol) and triethylamine (0.12 mL, 0.88 mmol) in DcM (10 mL). The 
solvent was evaporated in vacuo and the residue was purified by flash chromatography [on 
silica gel; elution with hexane-EtOAc (7:3)] to yield diethyl N-benzyl-2-[N-(3- 
nitrobenzyl)acetamido]ethylphosphoramidate 32e, a light green oil (5.3 mg, 3.8 %). SH/ppm 
(600 MHz; cDcU) 1.10 (6H, t, J = 7.2 Hz, 2 x cH3), 2.02 (3H, s, cH3cO), 2.81 (2H, m, N-cH2), 
3.32 (2H, t, J = 6.4 Hz, N-cH2), 3.81 (2H, s, ph-cH2), 4.07 (4H, m, 2 x pOcH2), 4.79 (2H, s, 
OcH2Ph) and 7.19 -  8.07 (9H, m, Ar-H); Sc/ppm (600 MHz; cDcfe) 14.4 (d, Jp-c = 5.9 Hz, 2 x 
cH3), 17.4 (cH3cO), 35.0 (d, Jp-c = 5.4 Hz, NcH2), 68.6 (d, Jp-c = 16.8 Hz, N-cH2), 60.0 (d, J p-c = 
6.7 Hz, 2 x POcH2), 66.8 (Ph-cH2), 74.3 (OcH2Ph), 120.8-146.9 (2 x Ar-c), 164.6 (c=O).
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Diethyl W-benzyloxy-2-[W-(3,4- dichlorobenzyl)acetamido]ethylphosphoramidate 32f
acetamido]ethylphosphoramidate 32a was employed, using diethyl N-[2-(benzyloxyamino)- 
ethyl]-N-(3,4 dichlorobenzyl)phosphoramidate 31f (0.27 g, 0.64 mmol), acetyl chloride (0.12 
mL, 1.3 mmol) and triethylamine (0.12 mL, 0.88 mmol) in DcM (10 mL). The solvent was 
evaporated in vacuo and the residue was purified by flash chromatography [on silica gel; 
elution with hexane-EtOAc (7:3)] to yield Diethyl N-benzyloxy-2-[N-(3,4-dichlorobenzyl)- 
acetamido]ethylphosphoramidate 32f, a yellow oil (5.8 mg, 2.9 %). SH/ppm (600 MHz; 
cDcl3) 1.11 (6H, t, J = 7.2 Hz, 2 x c-U), 2.02 (3H, s, cH3cO), 2.81 (2H, m, N-cH2), 3.32 (2H, t, J 
= 6.4 Hz, N-cH2), 3.81 (2H, s, Ph-cH2), 4.07 (4H, m, 2 x POc-h), 4.79 (2H, s, Oc^Ph) and 6.88 
- 7.19 (8H, m, Ar-H); Sc/ppm (600 MHz; cDcU) 14.5 (d, Jp-c = 5.9 Hz, 2 x cH3), 17.7 (cH3cO), 
35.0 (d, Jp-c = 5.4 Hz, NcH2), 49.2 (d, Jp-c = 16.8 Hz, NcH2), 60.5 (d, Jp-c = 6.7 Hz, 2 x POcH2), 
68.4 (Ph-cH2), 74.3 (OcH2Ph), 127.2-141.9 (2 x Ar-c), 164.2 (c=O).
Diethyl M-benzyl-2-(M-hydroxyacetamido)ethylphosphoramidate 33a
Cl
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The procedure described for the synthesis of diethyl N-benzyl-2-[N-benzyloxy)-
18
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A solution of diethyl N-benzyl-2-[N-benzyloxy)acetamido]ethylphosphoramidate 32a (0.20 g, 
0.46 mmol) in dry MeOH (2 mL) was added to a solution of Pd/c (10 %, 0.35 g) in dry MeOH 
(10 mL) under an H2-atmosphere and the mixture was stirred at room temperature for 18 
hours. The reaction mixture was then filtered through a celite pad, the filtrate was 
evaporated in vacuo and the residue purified by flash chromatography [on silica gel; elution 
with hexane-EtOAc (3:1)] to yield diethyl N-benzyl-2-(N-hydroxyacetamido)ethyl- 
phosphoramidate 33a, a clear oil (80 mg, 80 %). S-/ppm (600 MHz; cDcU) 1.28 (6H, t, J = 7.2 
Hz, 2 x cH3), 1.83 (1H, s, N-OH), 2.08 (3H, s, cH3cO), 2.89 (2H, m, N-cH2), 3.21 (2H, t, J = 6.0 
Hz, N-cH2), 3.79 (2H, s, Ph-cH2), 4.17 (4H, m, 2 x POc-h) and 7.32 - 7.45 (5H, m, Ar-H); 
Sc/ppm (600 MHz; cDcU) 16.1 (d, J p-c = 7.2 Hz, 2 x c-b), 20.8 (cH3cO), 35.8 (d, J p-c = 5.0 Hz, 
N-cH2), 53.6 (d, J p-c = 16.5 Hz, N-cH2), 62.3 (d, Jp-c = 5.6 Hz, 2 x POcH2), 67.5 (Ph-cH2), 127.3 
(c-17), 128.3 (c-19 and c-15), 128.6 (c-18 and c-16), 137.4 (c-14 and 167.5 (c=O).
Diethyl-2-(W-hydroxyacetamido)-W-[4-(hydroxymethyl)benzyl]ethylphosphoramidate 33b
22
OH
N J 2 X H 3 21
O
23
9 O 3
The procedure described for the synthesis of diethyl N-benzyl-2-(N-hydroxyacetamido)ethyl- 
phosphoramidate 33a was employed, using diethyl-2-[(N-benzyloxy)acetamido]-N- 
[4(hydroxymethyl)benzyl]ethylphosphoramidate 32b (0.20 g, 0.43 mmol) in MeOH (2 mL) 
and pd/c (10 %, 0.33 g) in MeOH (10 mL). The solvent was evaporated in vacuo and the 
residue was purified by flash chromatography [on silica gel; elution with hexane-EtOAc (3:1)] 
to yield diethyl 2-(N-hydroxyacetamido)-N-[4-(hydroxymethyl)benzyl]ethylphosphoramidate 
33b (82 mg, 82 %). S-/ppm (600 MHz; cDcU) 1.32 (6H, t, J = 7.2 Hz, 2 x c-b), 1.91 (1H, s, N- 
OH), 2.12 (3H, s, cH3cO), 2.80 (2H, m, N-cH2), 3.38 (2H, t, J = 6.4 Hz, N-cH2), 3.85 (2H, s, Ph-Page 104
cH2), 4.12 (4H, m, 2 x POcH2), 5.10 (2H, s, cH2OH), 7.25 - 7.30 (4H, m, Ar-H) and 8.02 (1H, s, 
cH2OH); Sc/ppm (600 MHz; cDcfe) 16.3 (d, Jp-c = 6.1 Hz, 2 x cH3), 23.4 (cH3cO), 37.4 (d, Jp-c =
5.2 91 Hz, N-cH2), 52.5 (d, Jp-c = 16.5 Hz, N-c-h), 63.6 (d, J p-c = 5.8 Hz, 2 x POcH2), 66.4 
(cH2OH), 68.8 (Ph-cH2), 123.4 (c-19 and c-15), 123.7 (c- 1 8  and c-1 6 ), 136.6 (c-14), 138.3 (c- 
17) and 170.1 (c=O).
Diethyl W-(3-aminobenzyl)-2-(W-hydroxyacetamido]ethylphosphoramidate 33c
N H 2
24
22OH9 O  3
21
16
17
The procedure described for the synthesis of diethyl N-benzyl-2-(N-hydroxyacetamido)ethyl- 
phosphoramidate 33a was employed, using diethyl N-(3-aminobenzyl)-2-[(N-
benzyloxy)acetamido]ethylphosphoramidate 32c (0.20 g, 0.44 mmol) in MeOH (2 mL) and 
Pd/c (10 %, 0.33 g) in MeOH (10 mL). The solvent was evaporated in vacuo and the residue 
was purified by flash chromatography [on silica gel; elution with hexane-EtOAc (3:1)] to yield 
diethyl N-(3-aminobenzyl)-2-(N-hydroxyacetamido]ethylphosphoramidate 33c (70 mg, 70 
%). SH/ppm (600 MHz; cDcfe) 1.29 (6H, t, J = 6.8 Hz, 2 x cH3), 2.14 (3H, s, cH3cO), 2.69 (2H, 
m, N-cH2), 3.26 (2H, t, J = 6.8 Hz, N-cH2), 3.81 (2H, s, Ph-c-h), 4.09 (4H, m, 2 x POcH2), 4.78 
(2H, s, NH2), 5.68 (1H, s, OH) and 6.59 - 7.16 (4H, m, Ar-H); Sc/ppm (600 MHz; cDcl3) 16.3 
(d, J p-c = 6.2 Hz, 2 x cH3), 21.5 (c^cO ), 36.4 (d, Jp-c = 4.7 Hz, N-c-h), 53.2 (d, Jp-c = 16.4 Hz, 
N-cH2), 62.2 (d, J p-c = 6.5 Hz, 2 x POcH2), 68.3 (Ph-cH2), 114.0 (c-17), 114.7 (c-19), 118.6 (c- 
15), 129.6 (c-16), 136.7 (c-14), 148.2 (c-18) and 166.6 (c=O).
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Diethyl 2-(M-hydroxyacetamido)-M-(3-mercaptobenzyl)ethylphosphoramidate 33d
1
10
16
2<9 O  3
S H24
■ CHs 21
The procedure described for the synthesis of diethyl N-benzyl-2-(N-hydroxyacetamido)ethyl- 
phosphoramidate 33a was employed, using diethyl 2-[(N-benzyloxy)acetamido]-N-(3- 
mercaptobenzyl)ethylphosphoramidate 32d (0.20 g, 0.43 mmol) in MeOH (2 mL) and Pd/c 
(10 %, 0.33 g) in MeOH (10 mL). The solvent was evaporated in vacuo and the residue was 
purified by flash chromatography [on silica gel; elution with hexane-EtOAc (3:1)] to yield 
diethyl 2-(N-hydroxyacetamido)-N-(3-mercaptobenzyl)ethylphosphoramidate 33d (71 mg, 
71 %). S-/ppm (600 MHz; cDcfe) 1.30 (6H, t, J = 6.8 Hz, 2 x cH3), 1.87 (1H, s, OH), 2.12 (3H, s, 
cH3cO), 2.71 (2H, m, N-cH2), 3.08 (1H, s, SH), 3.29 (2H, t, J = 6.8 Hz, N-cH2), 3.83 (2H, s, Ph- 
cH2), 4.09 (4H, m, 2 x POcH2) and 6.61 - 7.18 (4H, m, Ar-H); Sc/ppm (600 MHz; cDcU) 16.4 
(d, J p-c = 6.0 Hz, 2 x cH3), 22.4 (cH3cO), 36.4 (d, J p-c = 4.8 Hz, N-cH2), 48.7 (d, J p-c = 16.5 Hz, 
N-cH2), 61.5 (d, J p-c = 6.5 Hz, 2 x POc-h), 66.6 (Ph-cH2), 124.2 (c-15), 125.0 (c-19), 127.8 (c- 
17), 128.3 (c-16), 129.6 (c-18), 137.2 (c-14) and 163.0 (c=O).
W-Benzyl-2-(W-hydroxyacetamido)ethylphosphoramidic acid 34a
1
O H
18
O H
7ho ■ /
- N -
N ®  C H 3 17
O
19
3  1
4
5
9
12
10
14
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Trimethylsilyl bromide (0.15 mL, 1.0 mmol) was added drop-wise to diethyl N-benzyl-2-(N- 
hydroxyacetamido)ethylphosphoramidate 33a (0.12 g, 0.34 mmol) in DcM (5 mL) under N2 
at 0 0c and the mixture was stirred for 1 hour. The mixture was allowed to warm to room 
temperature, water was added (1 mL) and the resulting mixture was stirred overnight. After 
completion, the solvent was removed in vacuo and the residue chromatographed 
[preparative layer chromatography on silca; elution with hexane-EtOAc-MeOH (1:1:1)] to 
yield N-benzyl-2-(N-hydroxyacetamido)ethylphosphoramidic acid 34a (50 mg, 63 %). 
SH/ppm (600 MHz; D2O) 2.09 (3H, s, c-bcO), 2.79 (2H, m, N-c-h), 3.34 (2H, t, J = 6.4 Hz, N- 
cH2), 3.83 (2H, s, Ph-cH2), 5.25 (1H, s, N-OH), 7.29 - 7.37 (5H, m, Ar-H) and 8.15 (2H, s, 2 x 
OH); Sc/ppm (600 MHz; D2O) 20.7 (cH3), 42.6 (d, J p-c = 4.7 Hz, N-cH2), 52.3 (d, J p-c = 16.9 Hz, 
N-cH2), 67.2 (Ph-cH2), 126.4 (c-14), 128.6 (c-11 and c-15), 129.4 (c-13 and c-15), 139.4 (c- 
10) and 171.5 (c=O).
2-(W-Hydroxyacetamido)-W-[4-(hydroxymethyl)benzyl]ethylphosphoramidic acid 34b
7 HO 2
OH 
\ 8 •CH3 174
9
The procedure described for the synthesis of N-benzyl-2-(N-hydroxyacetamido)ethyl- 
phosphoramidic acid 34a was employed, using diethyl 2-(N-hydroxyacetamido)-N-[4- 
(hydroxymethyl)benzyl]ethylphosphoramidate 33b (0.12 g, 0.31 mmol) and TMSBr (0.12 mL,
0.93 mmol) in DcM (5 mL). The solvent was removed in vacuo and the residue 
chromatographed [preparative layer chromatography on silca; elution with hexane-EtOAc- 
MeOH (1:1:0.5)] to yield 2-(N-hydroxyacetamido)-N-[4-(hydroxymethyl)benzyl]ethyl- 
phosphoramidic acid 34b (53 mg, 65 %). S-/ppm (600 MHz; D2O) 1.76 (1H, s, cH2OH), 2.07 
(3H, s, cH3cO), 2.75 (2H, m, N-cH2), 3.27 (2H, t, J = 6.0 Hz, N-cH2), 3.82 (2H, s, Ph-cH2), 4.78
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(2H, s, cH2OH), 6.67 (1H, s, N-OH), 7.09 - 7.24 (4H, m, Ar-H) and 8.92 (2H, s, 2 x OH); Sc/ppm 
(600 MHz; D2O) 20.3 (cH3), 37.5 (d, JP -c  = 5.1 Hz, N-cH2), 51.8 (d, JP -c  = 16.6 Hz, N-cH2), 
65.7 (cH2OH), 68.4 (Ph-cH2), 126.2 (c-14 and c-12), 128.3 (c-15 and c-11), 136.5 (c-10),
139.2 (c-13) and 166.3 (c=O).
W-(3-Aminobenzyl)-2-(W-hydroxyacetamido)ethylphosphoramidic acid 34c
NH2
20
C H 3 17
The procedure described for the synthesis of diethyl N-benzyl-2-(N-hydroxyacetamido)ethyl- 
phosphoramidic acid 34a was employed, using diethyl N-(3-aminobenzyl)-2-(N-hydroxy- 
acetamido)ethylphosphoramidate 33c (0.10 g, 0.27 mmol) and TMSBr (0.10 mL, 0.81 mmol) 
in DcM (5 mL). The solvent was removed in vacuo and the residue chromatographed 
[preparative layer chromatography on silca; elution with hexane-EtOAc-MeOH (1:1:0.5)] to 
yield N-(3-aminobenzyl)-2-(N-hydroxyacetamido)ethylphosphoramidic acid 34c (40 mg, 57 
%). S-/ppm (600 MHz; D2O) 2.08 (3H, s, c^ cO ), 2.81 (2H, m, N-cH2), 3.28 (2H, t, J = 6.0 Hz, 
N-cH2), 3.60 (2H, s, Ph-cH2), 4.66 (1H, s, N-OH), 5.48 (2H, s, NH2), 7.00 (2H, s, 2 x OH) and 
7.10 - 7.29 (4H, m, Ar-H); Sc/ppm (600 MHz; D2O) 19.8 (cH3), 36.7 (d, Jp-c = 4.9 Hz, N-c-h), 
53.0 (d, J p-c = 16.5 Hz, N-cH2), 68.1 (Ph-cH2), 113.9 (c-13), 114.7 (c-15), 117.8 (c-11), 128.4 
(c-12), 138.3 (c-10), 146.5 (c-14) and 166.8 (c=0).
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2-(W-Hydroxyacetamido)-W-(3-mercaptobenzyl)ethylphosphoramidic acid 34d
12
13 15
S H
20
17
The procedure described for the synthesis of diethyl N-benzyl-2-(N-hydroxyacetamido)ethyl- 
phosphoramidic acid 34a was employed, using diethyl 2-(N-hydroxyacetamido)-N-(3- 
mercaptobenzyl)ethylphosphoramidate 33d (0.12 g, 0.31 mmol) and TMSBr (0.13 mL, 92 
mmol) in DCM (5 mL). The solvent was removed in vacuo and the residue chromatographed 
[preparative layer chromatography; elution with hexane-EtOAc-MeOH (1:1:1)] to yield 2-(N- 
hydroxyacetamido)-N-(3-mercaptobenzyl)ethylphosphoramidic acid 34d (48 mg, 68 %). 
SH/ppm (600 MHz; D2O) 2.09 (3H, s, CH3CO), 2.68 (2H, m, N-CH2), 2.80 (1H, s, SH), 3.33 (2H, 
t, J = 6.0 Hz, N-CH2), 3.84 (2H, s, Ph-CH2) and 6.85 -  7.37 (4H, m, Ar-H); SC/ppm (600 MHz; 
D2O) 22.4 (CH3), 40.6 (d, J p-c = 4.8 Hz, N-CH2), 52.7 (d, J p-c = 16.5 Hz, N-CH2), 68.2 (Ph-O-h),
119.2 (C-11), 123.1 (C-15), 126.6 (C-13), 129.4 (C-12), 130.2 (C-14), 138.5 (C-10) and 162.1 
(C=0).
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3.2. Docking Studies
The ligand structures (2-4, a-c and R-group) were constructed using Discovery Studio 
Visualiser,178 each with two water molecules near the phosphonate group. An in vacuo 
global energy was located for each of the ligands using conformational lowest Energy_dlgfn 
in autodock tools.179 The lowest energy conformers were then subjected to geometry 
optimisation in Gaussian. The crystal structure of the proteins (1Q0L, 1Q0Q, 2EGH, 3AU8, 
3AU9 and 3AUA) were obtained from a Protein Data Bank.163 The protein structures were 
dehydrated, while the divalent cation (Mg2+) and co-factor NADPH were retained and the 
template ligand removed then re-docked along with the constructed ligands.
The geometry optimised and energy minimised ligands were imported into AutoDock 4.2 
experiments using putty. All possible conformations of the ligands were allowed with 
flexible residues assigned to the protein active site (Ser270, Ser306, Asn311, Lys312 and 
Glu315) to allow uniform binding of ligands.
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